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Ste Iii ngen behorende bij het proefsch rift 
Diagnostic assessment of orofacial pain 
1. Wanneer de criteria voor interne validiteit conform de Quality Assessment of Diagnostic Accuracy Studies (QUADAS) lijst worden gevolgd bij het opzetten van een wetenschappelijk onderzoek in het domein 'diagnostiek', is de kans groot dat deze studie wordt gei'ncludeerd in systematische reviews en dus zal bijdragen aan de beschikbare 'evidence'. (dit proefschrift) 
2. Het pijnverminderend effect van intra-articulaire anesthesie van het kaakgewricht bij patienten met preauriculaire pijn moet worden gei'nterpreteerd tegen de achtergrond van het placebo-effect. (dit proefschrift) 
3. Een placebo is niet niks. (dit proefschrift) 
4. Optimalisatie van de farmacologische test ten behoeve van de diagnostiek van chronische pijn zal primair gericht moeten zijn op vermogen nociceptieve van niet­nociceptieve pijn te onderscheiden. (dit proefschrift) 
5. Work expands so as to fill the time available for its completion. (C.N. Parkinson 1955) 
6. Het diagnosticeren en succesvol behandelen van een somatische aandoening sluit aanwezigheid van een psychologische component niet uit. 
7. De term "studie medicijnen" zou toepasselijker zijn voor de studie farmacie clan voor de geneeskundestudie. 
8. Tandartsen die zich bij het verantwoorden van hun handelen uitsluitend beroepen op "jarenlange ervaring", maskeren daarmee gebrek aan theoretische kennis. 
9. Geld lenen is omgekeerd (en duur) sparen. 
10. Het grote aantal talentenjachten op televisie vermindert de waarde van het winnen ervan. 
11. In theorie liggen praktijk en theorie dicht bij elkaar, in de praktijk is dat vaak niet zo. 
12. Een periodiek mondonderzoek zonder parodontale screening is een kunstfout. 
13. Een stelling over stellingen begrijpt niet iedereen. 
Geerten-Has E. Tjakkes, 17 november 2010 
C:..·nu· .. !t. U 
f·tbhmh-,··k Groning.:n 
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The International Association for the Study of Pain (IASP) has defined pain as 
'an unpleasant sensory and emotional experience associated with actual or potential tissue 
damage or described in terms of such damage' (Merskey and Bogduk, 1994). 
According to this definition, there are two main issues associated with pain, i.e.: 
1. tissue damage is involved. 
2. it refers to an individual experience. 
This emphasizes the importance of a bi-axial approach of pain, including a physical as 
well as a psychosocial axis (Okeson, 2005). 
Chronic pain is usually defined as pain without apparent biologic value that has persisted 
beyond the normal tissue healing time (which is about 3 months) (Zakrzewska and Har­
rison, 2002; Palla, 2006 ). This term is used in contrast with acute pain, which is pain due 
to tissue damage, infection or inflammation (Sternbach, 197 4 ). 
Chronic pain may develop from an ineffectively or inadequately (albeit unintentionally) 
treated acute pain condition. A coinciding problem is that, when pain persists over time, 
neuroplastic changes may occur and psychosocial behavioral changes tend to become 
more influential. Chronicity of pain involves anatomical, physiological, psychological, 
neurochemical, and genetic changes that make evaluation difficult. 
Signals from the nociceptors terminate in the caudal nucleus of the medullar trigeminal 
system. After prolonged nociceptive input, the dendritic nerve terminals release chemi­
cal mediators, such as glutamate, substance-P, and calcitonin gene-related peptide. These 
mediators modulate the excitability of neuronal membranes in the dorsal horn of the 
spinal cord and medulla, leading to sensitization of the second order neurones. This 
process is termed 'central sensitization' (Dubner and Ren 2004). The prolonged signal­
ling cascades in second-order nociceptive neurons elicited by subsequent close-spaced 
stimuli lead to an increase in the action potential discharge, a phenomenon referred to as 
"windup" (Salter 2004). In addition to an increase in the expression of excitatory trans­
mitters, inhibitory mechanisms may be suppressed, thus contributing to sensitization. 
Recently the influence of non-neuronal (glial) cells has been suggested as a point of focus 
in neuroplasticity. Hyperactive glial cells appear to be involved in the modulation of 
trigeminal spinal subnucleus caudalis (V c) and spinal dorsal horn activity after inflamma­
tion or peripheral nerve injury (Okada-Ogawa et al., 2009). Related to this mechanism, 
the enzyme aconitase and astroglial-dependent glutamine supply has been suggested to 
be relevant in sustaining enhanced neuronal activity related to chronic pain mechanisms 
(Okada-Ogawa et al., 2009). 
Clinically, central sensitization may give rise to secondary hyperalgesia, i.e. a lowering 
of the pain threshold and increased response to noxious stimuli (Merskey and Bogduk, 
10 
1994 ). Allodynia is another phenomenon associated with sensitization, which is char­
acterized by a painful and persistent pain response to a normally non-noxious stimu­
lus (Henry, 2004 ). In addition to the aforementioned hyperphenomena, sensory deficits 
such as hypesthesia (decreased sensitivity to stimulation excluding the special senses), 
hypalgesia (diminished pain in response to a normally painful stimulus), as well as par­
esthesia (an abnormal sensation, whether spontaneous or evoked) and dysesthesia (an 
unpleasant abnormal sensation, whether spontaneous or evoked) may occur (Merskey 
and Bogduk, 1994 ). 
The neuroplastic changes may also lead to different kinds of heterotopic pain, i.e. pain 
that is felt in another area than the location of the source. In projected pain the site where 
the pain is felt lies distally in the distribution of the same nerve as the source of pain. 
Referred pain is also felt at another site than the source, but this site does not necessar­
ily lie within the distribution of the same nerve, but rather at the same segmental level 
(Okeson, 2005). 
Biaxial diagnosis of pain conditions 
Currently, it is generally agreed to establish a pain diagnosis in a biaxial system. Axis I 
concerns the somatic diagnosis (related to the underlying tissue damage), and axis II 
expresses the functional and psychosocial impact of the pain experience on the patient. 
As chronic pain is unrelenting, stress, environmental, and affective factors may likely su­
perimpose on the effects of the damaged tissue(s) and, therefore, likely contribute to the 
perceived intensity and persistence of pain (Loeser and Melzack, 1999; Dworkin, 2001). 
In most common orofacial pain conditions, establishing an axis I diagnosis is relatively 
easy, and the source of pain may be identified based on the patient's complaints and using 
routine diagnostic tests, such as provocation and/ or anesthesia tests. It should be noted 
that psychological factors play a role in all types of pain, irrespective of its duration. In 
longer lasting and chronic pain conditions, however, psychosocial factors become more 
prominent and even may dominate and obscure the clinical presentation. A shift in the 
origin of pain from somatosensory input to affective, cognitive, and behavioural inputs 
of pain may take place (Okeson, 2005). After a more extended duration of pain, either 
with a constant, decreased or even a disappeared somatosensory input, the level of suf­
fering is likely to increase. In cases where axis II factors dominate, this should be a seri­
ous and significant part of the diagnostic assessment as well as of the therapy, even more 
than in (sub)acute situations. This is confirmed by the finding that psychological factors 
are better predictors of treatment outcome in patients with chronic pain conditions than 
somatic findings (Turk and Okifuji, 2002; Dworkin, 2006). 
Health beliefs 
During the past decades, there has been an enormous shift in health beliefs ( of patients 
and clinicians), such as the importance of a certain life style (alcohol consumption, to­
bacco smoking, food consumption, physical exercise) in relation with several diseases 
(e.g. cancer, heart diseases) (World Cancer Research Fund, 2007). In contrast, most pain 
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patients (as well as many doctors) still tend to approach chronic pain from a biomedical 
point of view (Feinmann, 2004). The inability to identify the cause of or to offer a cure 
for the pain is often interpreted as the failure of the examination or tests used to establish 
a diagnosis or as insufficient competence of the clinician to deal with the problem. This 
may either lead to repetition of examinations or tests or to visiting other clinicians, thus 
contributing to "medical shopping" behaviour (Feinmann, 2004). In turn this may lead 
to a frustrated patient, who is led to think that the medical system is unable to cure him 
or her. This may lead to a change in attitude of the patient towards the clinician, which 
in turn may be interpreted by the clinician as underlying psychopathology. Biomedically 
oriented clinicians consider attention for the effect of the pain on the patient's daily life 
as being unimportant as it is not biology-based. Introverted interest in psychological fac­
tors may lead to the belief that the pain is imaginary or made up by the patient (Dworkin, 
2001). This complicates and frustrates the patient-doctor-relationship as well as the out­
come of further assessment and treatment of the chronic ( orofacial) pain patient. 
The state of the current knowledge of orofacial pain is, however, hardly represented by 
the current practice in oral health care; outdated diagnostic procedures are still used; the­
ories explaining diseases that have been disproved are still communicated to patients and 
inappropriate or harming treatments are still offered (Greene, 2001; Klasser and Greene, 
2009). 
Classification of pain conditions 
In (medical) science, classification systems are thought to be essential for epidemiologi­
cal studies, clinical decision making, treatment planning, the indication of treatment, and 
the evaluation of treatment efficacy (Zakrzewska, 2002). There is, however, a continuing 
controversy in the classification and definitions of disease (Scadding, 1996 ). One part of 
the controversy lies in the distinction between realists, who are in this context referred 
to as "essentialists", and "nominalists". The essentialists' definition starts with "X is .. . " 
which presupposes the existence of something that can be identified as X. On the other 
hand, nominalists typically would say "X refers to ... ,, , which explains the sort of obser­
vations that are required to test the truth of sentences, including hypotheses, in which X 
occurs. (Scadding, 1996 ). So in nominalism, a classification is based on the resemblance of 
signs and symptoms in a group of patients. In relation to this, Turk and Rudy have made 
the distinction between pain classifications based on theoretical background and those 
based on empirism. (Turk and Rudy, 1992) 
In a theoretical classification, a group of signs and symptoms are thought to be unique 
for a disease and, therefore, able to differentiate between subjects. Examples of classifica­
tion systems using a theoretical classification for pain in the orofacial region include clas­
sifications of the International Headache Society (IHS), the International Association for 
the Study of Pain (IASP), the American Association for Orofacial Pain (AAOP), and the 
Research Diagnostic Criteria for Temporomandibular Disorders (RDC/TMD). In the 
empirical approach, a set of variables which characterizes a group is identified. Exam­
ples of this approach are instruments as the Symptom Checklist SCL-90 and the McGill 
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Pain Questionnaire (MPQ) and the West-Haven Yale Multidimensional Pain Inventory 
(WHYMPI or MPI). The MPI was used in a group of patients with temporomandibu­
lar disorders (TMD). After cluster analysis, three groups could be indentified and were 
labeled "dysfunctional", "interpersonal distressed" and "adaptive copers" (Rudy et al., 
1989). So apparently, using an empirically derived classification system was able to (al­
ternatively) classify TMD patients, irrespective of the origin or nature of the disease. 
Remarkably, the theoretically based classification systems are more frequently used than 
the empirical classification systems. With regard to the orofacial area, the classification 
system of the IASP (Merskey and Bogduk, 1994) results in a collection of groups of so 
called "relatively localized syndromes of the head and neck". The pain conditions are 
classified by pain characteristics, i.e. main features, pathology, course, complications, and 
differential diagnosis where possible. 
The IHS has introduced a classification system where facial pain diagnoses, mainly re­
lated to headaches in the broadest sense, are described by diagnostic criteria obtained by 
consensus (Olesen, 2004). The pain conditions are classified according to phenomenol­
ogy, and with each condition a description of its characteristics is provided together with 
diagnostic criteria required to be satisfied. With regard to orofacial pain, this classifica­
tion system has been extended by the AAOP (McNeill, 1993; Okeson, 1996; de Leeuw, 
2009), which is widely used by workers in this field. 
It is generally agreed that pain in the orofacial region that has become chronic is a com­
plex problem for the patient as well as for the clinician. The IHS, IASP, AAOP and 
RDC/TMD criteria represent most acute conditions, but chronic pain problems only 
partly. However, this may be due to obscure presentation and symptoms, some chronic 
pains cannot be classified using these criteria. This is illustrated by the terms used in 
the literature to designate these problems, i.e. 'atypical facial pain', 'atypical odontalgia', 
'chronic pain syndrome', 'idiopathic chronic (orofacial) pain'. It is not clear whether 
these pain types are distinct or that they show resemblance to each other or are distin­
guished by location (Aggarwal et al, 2007). One of the characteristic features is that these 
conditions are complex and are ( often) diagnosed per exclusionem. Especially in these 
cases, information gained by history taking alone may be insufficient and further diag­
nostic information is desirable. 
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General aim of this thesis 
As can be derived from the aforementioned, chronic pain is a complex matter. Pain is 
often considered as a symptom of a disease, and this is likely the case in acute situations. 
However, when severe or persistent, the underlying tissue damage may resolve while the 
pain persists and becomes chronic. In these cases, the pain experience has become the 
main component of the condition. Chronic pain presents with its own symptoms, such 
as disability, depression and sleep disturbances and the pain should be considered as the 
disease itself (Niv and Devor, 2004 ). Nevertheless, when a patient attends the clinician 
with a chronic pain problem, the pain is often primarily considered as a symptom of un­
derlying disease and the patient often expects to be diagnosed and subsequently treated 
accordingly. This is the key of the problem with which the clinician is faced. 
Current classification and assessment procedures may be unable to elucidate causes or 
underlying mechanisms of pain and have there/ ore not led to a diagnosis and subsequent 
satisfactory treatment. Alternative diagnostic procedures may give valuable insight in the 
patient's pain problem. 
In relation to the bi-axial approach, Loeser developed a pain model, which illustrates in a 
simplified manner how different dimensions of pain may be imagined. These dimensions 
are illustrated by a series of overlapping circles (Loeser and Black, 1975 ). These four dif­
ferent dimensions do not necessarily occur in every body, nor do they occur to the same 
extent. In fact, the relative size of the circles in the model may vary per patient. There­
fore, the assessment of the influence and importance of these different levels in orofacial 






The smallest circle represents the noxious stimulus (nociception; activation of nerve fib­
ers). The surrounding circle is referred to as perception of pain, which is influenced by 
phenomena such as hyperalgesia, allodynia, hypesthesia, hypalgesia, paresthesia and dys­
esthesia. Pain perception frequently results from an underlying noxious stimulus (nocic­
eptive pain), but may also be generated by lesions within the peripheral or central nerv­
ous system. (Loeser and Melzack, 1999). Pain perception, especially when pain exists 
over a longer period of time, may lead to suffering. Suffering is a response induced by 
pain, but it is also induced by e.g. fear, anxiety, stress, and other psychological states. In 
turn, the suffering affects the patients' pain behaviour. Pain behaviour is observable and 
quantifiable. 
In an adapted, simplified version of this model, pain could be illustrated as follows: 
experience 
This figure shows that pain originates from damage. Whether the damage is currently 
present or not, in both situations the processing of damage will eventually lead to pain 
experience. So, pain involves (originally) a stimulus, which after processing has conse­
quences, such as psychological and social ones. The Stimulus-Processing-Consequences­
model (SPC-model) illustrates this: 
In assessing patients with pain, the focus could be on the origin of the pain, but alterna­
tively, it could be on one or more of the abovementioned three SPC levels. The (location 
of the) stimulus could be targeted by means by provocation, but alternatively also by lo­
cal anesthesia. The effect of pharmacological agents could be of help in the assessment of 
patients, giving more insight in the pain problem. We refer to the diagnosis of pain using 
pharmacological agents as pharmacodiagnostics. So, pharmacodiagnostics can be per-
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formed locally but also systemically. Theoretically, both the levels stimulus and process­
ing can also be affected by systemic pharmacodiagnostics, providing additional informa­
tion for subsequent treatment. Chronic pain has a functional as well as a psychosocial 
impact, implying significant psychological and social consequences patients' experience, 
which is reflected by the quality of life (QoL). Attention in diagnostic assessment should 
therefore also be given on the third level, the consequences. In this, QoL could therefore 
be the focus in examination and assessment of chronic pain patients. 
In short, the general aim of this thesis is to enhance the diagnostic assessment in chronic 
orofacial pain, by focusing on three basic components of pain, i.e. the stimulus, the pro­
cessing of the pain signal, and the consequences of pain. 
Specific aims 
In order to facilitate the diagnostic process in orofacial pain patients, numerous diag­
nostic tests have already been suggested and used. However, the evidence for diagnostic 
validity and their clinical relevance as well as the feasibility of these tests differ and are 
sometimes even lacking. Whether a test was properly studied, under which conditions, is 
suitable for use and what can be concluded from it remains unclear. 
To provide an overall overview and appraisal of the currently used and qualitatively well­
studied diagnostic tools in chronic orof acial pain, a systematic review of the current litera­
ture is presented in chapter 2. 
Orofacial pain refers to pain originating below the orbitomeatal line, above the neck, 
and anterior to the ears (Zakrzewska 1999). Most commonly, orofacial pain originates 
from the dentoalveolar area, and usually involves an inflammatory response related to an 
infection or traumatic injury. The most common cause for orofacial pain is dental pain, 
e.g. caused by caries, pulpitis, or periodontal disorders. The prevalence of dental pain is 
associated with the prevalence of caries, which, in turn, depends on the diet, social class, 
fluoride intake, and oral hygiene (LeResche 2001). In a community-based study, Mac­
farlane et al. found an overall orofacial pain prevalence of 26% (Macfarlane et al., 2002). 
For pain in the temporomandibular area, which represents another common group of 
orofacial pain complaints, an average estimated prevalence of 10% was found (LeResche, 
1997). After a proper diagnosis is made in these conditions, subsequent treatment may be 
initiated and will, in most cases, be successful. 
In the (sub )acute cases, such as the aforementioned painful conditions, the diagnostic 
process will be relatively straightforward, as the presentation of the complaints is usually 
characteristic for these conditions. In these cases, the importance and influence of the 
nociceptive level will be relatively large and the emphasis in diagnosis and treatment will 
be mainly (but not exclusively) on this dimension. 
In the process of identification of the structure with tissue damage and from which the 
pain emanates, provocation-tests are usually performed. When the site and source of the 
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pain are not the same ( e.g. in secondary pain), local provocation of the site of pain will 
not increase the pain, whereas local provocation of the source of pain will increase the 
pain, not only at the source of pain but also at the site (Okeson, 2005). In addition, local 
anesthesia can be used in establishing the source of pain. When the site and source are not 
the same, local anesthetic blocking of the site of pain will not decrease the pain, and local 
anesthetic blocking of the source of pain will decrease the pain at the source as well as 
the site (Okeson, 2005). This technique has been previously propagated, for example for 
trigger points in myofascial pain conditions. Also in patients where the pain is suspected 
to be of pulpal origin, local anesthesia is frequently used to establish the site of pain. In 
patients with temporomandibular disorders, several tests that focus on provocation have 
been described (Visscher et al., 2009). In these patients, administration of local anesthe­
sia could aid in establishing the source of pain. However, the distinguishing capacity of 
intra-articular temporomandibular joint (TMJ) anesthesia has never been studied, and 
the validity of such a test has never been established. 
Chapter 3 focuses on pharmacodiagnostics. In chapter 3. 1, a study is described with the 
aim of evaluating the distinguishing ability of intra-articular anesthesia from placebo in 
orofacial pain patients with pain located in the TM] region, aiming at a validation of 
intra-articular anesthesia injection as a diagnostic test for pain in the TM] region. 
Many factors have been suggested to be associated with (chronic) pain, most of which are 
addressed in history taking: premonitory symptoms, precipitating factors, onset of the 
pain, alleviating factors, environmental as well as social factors, family history, psycho­
logical and psychiatric history and medication use (Zakrzewska, 2002). Care should be 
taken not to jump to conclusions too soon. All collected information should be carefully 
weighed and integrated. Valuable additional information is gained from physical exami­
nation. Based on the collected information, a differential diagnosis can be made. In many 
cases, the combination of the history and the physical examination provides sufficient 
information to arrive at a definitive diagnosis or limited differential diagnosis. There is a 
need for more insight when the available information in chronic patients who have un­
dergone extensive history taking, physical examinations and additional diagnostic tests 
which did not yield sufficient information to come to a diagnosis or classification. 
Based on pain research that has been carried out during the past decade, different pain 
processing mechanisms have been described. The most common and prominent pain 
mechanisms include nociceptive pain, neuropathic pain, and sympathetically maintained 
pain (SMP). In chronic pain patients, knowledge of the mechanism(s) underlying or 
contributing to the clinical pain presentation may be valuable in further assessment and 
treatment. Therefore it seems legitimate to use pharmacological agents specifically aim­
ing at these mechanisms, in order to help to disentangle their effects. In this form of phar­
macodiagnostics, several pharmacological agents are used, in order to classify patients 
based on their response to administered agents. 
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In chapter 3. 2 pain diagnosis using pharmacological agents has been studied in different 
pain groups. Focusing on orofacial pain patients, a preliminary intravenous diagnostic test was developed and applied in the pain clinic. The results of performed pharmacodiag­
nostic tests and its potential distinctive ability were evaluated retrospectively, and the results are presented in chapter 3.2. Based on these result, the test was slightly modified. In chapter 3.3 the results of an analysis of its distinguishing ability between nociceptive 
pain, neuropathic pain, and sympathetically maintained pain are presented. The potential predictive validity of the test was studied by testing patients of whom the underlying pain 
mechanism (i.e. nociceptive, neuropathic and sympathetically maintained) was probable. 
The consequences of chronic pain may be far reaching, especially for the patient's qual­
ity of life. When the patient's daily life becomes dictated by pain, psychological changes 
and restrictions in lifestyle it is likely to result in limited capabilities. Recognition and 
acknowledgement of these factors may enhance the assessment, aid in the diagnostic 
process, and guide management of chronic orofacial pain patients. It is generally agreed, 
that the longer pain persists, the more it influences QoL. Whether this is really the case 
and, if so, to what extent, is still not clear. In addition, assessment of QoL can take place 
using standardized tools, although in chronic pain patients predetermined measures may 
be insufficient to incorporate all factors that determine an individual's QoL. Therefore, 
an alternative assessment method may be of additional value in QoL appraisal. 
Chapter 4 addresses the assessment of health-related quality of life (HRQoL) in patients 
with chronic orofacial pain. The aims of the study presented in chapter 4.1 were to as­
sess whether the HRQoL is decreased in chronic orofacial pain patients as compared to 
the general population, to study the differences in HRQoL between groups with differ­ent symptom duration, and to study the effect of the duration of symptoms on HRQoL. An exploration of an individualized approach in quality of life assessment in orofacial 
pain patients revealed additional information compared to the information obtained from 
standardized quality of life assessment. This study is presented in chapter 4.2. 
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Diagnostic tests in orofacial pain patients. 
A systematic review 
This chapter zs based on: Diagnostic tests in orof acial pain patients. A systematic review. 
Tjakkes GH, Huddleston Slater ]JR, Van Wijhe M, Stegenga B, submitted. 

Abstract 
Aims: In patients with persistent pain in the orofacial region, changes in the nervous 
system have been shown to occur. In addition, psychosocial factors become more promi­
nent. This has consequences for the diagnostic process and subsequent treatment of these 
patients. To assist the diagnostic process, several tools are available. The aim of this paper 
was to systematically assess the quality of clinical diagnostic tests currently performed in 
patients with persistent orofacial pain and, subsequently, to assess the clinical feasibility 
of these tests in patients with persistent pain. 
Methods: A literature search was performed, aiming at studies investigating diagnostic 
tests for different types of orofacial pain. Relevant studies were analyzed using a qual­
ity assessment tool for diagnostic accuracy (QUADAS). This tool consists of 14 items 
referring to internal validity. Studies scoring more than 50% of these items were further 
assessed for their clinical relevance and applicability. 
Results: When assessing the quality of the existing literature using a developed qual­
ity assessment tool, 15 articles were found to be of sufficient methodological quality. 
Especially studies concerning the use of magnetic resonance angiography in trigeminus 
neuralgia patients and the use of magnetic resonance imaging in patients with temporo­
mandibular arthralgia are well represented in the literature. 
Discussion: When literature concerning the diagnostic tests in orofacial pain conditions 
is reviewed and qualitatively appraised, only a minority remains, which concerns mainly 
well defined orofacial pain types. 
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Introduction 
In medical and dental practices, orofacial pain is a common reason for patients to seek 
treatment. To make a diagnosis in these patients, a full pain history is mandatory. The 
history should include the character, the mode of onset, the location, the duration as well 
as the periodicity, the referral pattern, and the severity of the pain. In addition, associated 
factors should be included: premonitory symptoms, precipitating factors, onset, allevi­
ating factors, environmental as well as social factors, family history, psychological and 
psychiatric history and medication use (Zakrzewska and Harrison, 2002). In combina­
tion with the physical examination, this will in the majority of cases provide sufficient 
information to arrive at a diagnosis. However, in chronic orofacial pain cases, despite 
a thorough history and physical examination, the cause and mechanism often remain 
unclear. These conditions are currently referred to as chronic idiopathic orofacial pain. 
Persistent pain in the orofacial region has been shown to give rise to changes in the nerv­
ous system (Sessle, 2000). These neuroplastic changes lead to altered pain perceptions 
such as referred pain, hyperalgesia, and allodynia. In addition, the effects of psychoso­
cial factors become more prominent (Dworkin, 2006 ). This complicates the diagnostic 
process and subsequent treatment of these patients. For the diagnostic classification of 
chronic idiopathic orofacial pain patients, the oral history and physical examination are 
frequently insufficient; hence additional investigations are required. A large variety of 
diagnostic tools have been developed and applied. The scientific rationale for their use is 
often inconclusive, and often based on clinical experience or what seems to be common 
sense. Therefore, in order to study the current diagnostic methods and their applicability 
in patients with persistent orofacial pain, it seemed worthwhile to systematically review 
the literature for the available evidence. 
The primary aim was to systematically review the literature with regard to diagnostic 
tests performed in patients with orofacial pain. Studies of satisfactory methodological 
quality were used to assess the clinical quality and applicability of the tests. 
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Methods 
Search methods for identification of studies 
Electronic search: 
A literature search was executed in Medline using Pubmed (Pubmed 1957-2008) and 
the Cochrane Database of Systematic Reviews. In table 1 the search terms are shown. 
For the purpose of identifying diagnostic publications, a methodological filter was used 
adapted from a recently published search string for publications concerning diagnostic 
accuracy (Deville et al., 2002). To retrieve literature concerning diagnostic tests studied in 
a randomized controlled design, a search string for randomized controlled trials (RCT's) 
was also used (Glanville et al., 2006) (figure 1). Articles in English, French, German and 
Dutch were selected. 
Searching other resources 
A manual cross-reference search of eligible studies was performed to find other relevant 
studies. 
Criteria for considering studies for this review 
The title, abstract, and key words of identified studies were screened independently by 
one reviewer for relevance to the systematic review. We have considered diagnostic stud­
ies in which the primary goal was to compare an index test with a reference test. Case 
reports, narrative reviews, editorials, letters, commentaries, duplicate publications of the 
same patient population, case-control trials and papers studying the efficacy of treat­
ment were excluded. To establish a broad search, no a priori restrictions with regard to 
the orofacial pain condition were used, and all studies carried out in primary, secondary 
and tertiary care were included. Studies using healthy volunteers with experimental pain 
were excluded. 
Assessment of methodological quality 
The quality of each study was assessed by two authors (GHT and JHS), using the Qual­
ity Assessment of Diagnostic Accuracy Studies list (QUADAS) (Whiting et al., 2003). 
This checklist consists of 14 items that refer to internal validity (table 2). Each item was 
scored as "yes" (positive assessment), "no" (negative assessment) or "unclear" (insuffi­
cient information), based on the description in the user's guide for the QUAD AS. In order 
to obtain qualitatively adequate studies, we argued that studies scoring "yes" in more 
than half (7) of the questions could be included for further appraisal. 
Inter-observer agreement (kappa) was calculated for agreement in inclusion of appro­
priate studies (Landis and Koch, 1977). Disagreement was be resolved by a consensus 
discussion or, if necessary by a third party (BS). 
Data extraction 
Two reviewers independently extracted data from the included studies and considered 
the following items: bibliographic details, details of the study setting, characteristics of 
study population, frequency and course of the tests, baseline and outcome measures. 
Uncertainties on data extraction were resolved by discussion between the reviewers. 
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Table 1 . Used search terms 
Pain diagnosis 
"Facial Pain" [Mesh] OR "Facial Neuralgia"[Mesh] OR "Toothache"[Mesh] OR "Trigemi-
nal Neuralgia"[Mesh] "Glossopharyngeal Nerve Diseases"[Mesh] OR "Burning Mouth 
Syndrome"[Mesh] OR "Temporomandibular Joint Dysfunction Syndrome"[Mesh] OR facial neural­
gia OR facial pain OR orofacial pain OR odontalgia OR trigeminal pain OR trigeminal neuralgia OR 
trigeminal postherpetic neuralgia OR trigeminal neuropathic pain OR glossopharyngeal neuralgia 
OR burning mouth OR temporomandibular joint pain OR craniomandibular pain OR TMJ pain 
Search string for diagnostic studies 
((((((("sensitivity and specificity"[AII Fields] OR "sensitivity and specificity/standards"[AII Fields]) 
OR "specificity"(AII Fields]) OR "screening"[AII Fields]) OR "false positive"(AII Fields]) OR "false 
negative"[AII Fields]) OR "accuracy"[AII Fields]) OR (((("predictive value"[AII Fields] OR "predic­
tive value of tests [All Fields]) OR "predictive value of tests/standards"[AII Fields]) OR "predictive 
values"[AII Fields]) OR "predictive values of tests"[AII Fields])) OR (("reference value"[AII Fields] 
OR "reference values"[AII Fields]) OR "reference values/standards"(AII Fields]) OR ((((((((("roc" [AI I 
Fields] OR "roe analyses"[AII Fields]) OR "roe analysis"[AII Fields]) OR "roe and"[AII Fields]) 
OR "roe area" [AII Fields]) OR "roe auc"[AII Fields]) OR "roe characteristics"[AII Fields]) OR "roe 
curve"[AII Fields]) OR "roe curve method"[AII Fields]) OR "roe eurves"[AII Fields]) OR ''roe 
estimated"[AII Fields] OR "roe evaluation"[AII Fields] OR "likelihood ratio"[AII Fields]) 
RCT terms 
Clinical trial[pt OR randomized[tiab] OR placebo[tiab) OR clinical trials(mh) OR randomly[tiab] OR 
trial[ti)) NOT (animals[mh) NOT (animals[mh) AND humans[mh))) 
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Figure 1 .  Search strategy 
Pubmed/Embase/Cochrane 
y 
Pa in  terms 
y 
Randomised Contro l led Tria l  terms 
y 
Diagnostic Tria l  terms 
y 
Abstract and tit le screen ing 
y 
Fu l l  artic le assessment: 11 6 
y 
Assessment us ing QUADAS : 44  
y 
Positive on more than 7 QUADAS criteria : 1 5  
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Table 2. Quality Assessment of Diagnostic Accuracy Studies l ist {QUADAS), used in this study to 
assess internal validity (Whiting et al., 2004) 
1 .  Was the spectrum of patients representative of the patients who wil l  receive the test in 
pr�? 
2. Were selection ootet.ia clean,y described? 
3. Is the refereace standard Hkely to oorrectly classify the target condition? 
4 . Is tbe time period between r;eference standard and index test short enough to be reason� 
sure that the target condition did not change: between the two tests? 
5 .  D id the whole sample or a random selection of the sample, receive verification using a ref 




11 . "Were the reference standard r.es1:Jlts interpreted without knowledge of tbe results of the 
index test? 
1 2. Were the same clinical data available when test results were interpreted as would be avail ­
ab le wben the test is used if.l practice? 
1 3. 
1 4. 
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Results 
Search results 
The search of the databases identified 107 4 articles. After screening the titles and ab­
stracts, 116 potentially relevant references were retrieved in full. After reading these full 
versions, 72 articles did not meet the inclusion criteria concerning purpose and design as 
mentioned earlier. Eventually, 44 articles were assessed using the QUADAS, of which 15 
studies were considered to be of adequate quality for further assessment, i.e. scored "yes" 
on the QUADAS in more than 7 of the 14 items. The manual cross-reference search of 
eligible studies was performed did not yield any other relevant studies. Inter-observer 
agreement was calculated for agreement in inclusion of appropriate studies. A consensus 
discussion was needed 7 times, and resolvement of disagreement by a third party was 
unnecessary. Kappa was: 0.81 (95% CI: 0.64-0.99). 
Description of the studies 
Of the 15 studies included, the design and outcome details are listed in table 3. The results 
of the qualitative appraisal using the QUADAS criteria of all studies are listed in table 4. 
Of all studies, eight investigated the diagnostic value of magnetic resonance angiogra­
phy (MRA) for vascular compression in trigeminal neuralgia (TN). Patients that were 
clinically suspect for trigeminal neuralgia and were referred for (surgical) treatment un­
derwent MRA. Subsequently, the surgery was performed (i.e., decompression was per­
formed in case of compression of the nerve) and the findings were compared with the 
findings during MRA (Anderson et al., 2006; Benes et al., 2005; Beecher-Schwartz et 
al., 1998; Fukuda et al., 2006; Korogi et al., 1995; Meaney et al., 1995; Patel et al., 2003; 
Voros et al., 2001). Of these studies, only Fukuda and co-workers used a two dimen­
sional MRA technique (Fukuda et al., 2006 ); the other studies used three dimensional 
MRA. Also, Fukuda included hemifacial spasm patients. In table 4 an overview of the 
MRA studies is provided. All studies were conducted in hospitals. Most patients were 
referred for decompression surgery (Anderson et al., 2006; Benes et al., 2005; Boecher­
Schwartz et al., 1998; Fukuda et al., 2006; Korogi et al., 1995; Meaney et al., 1995; Patel 
et al., 2003 ). Eligible patients underwent the imaging procedure, which was interpreted 
by a neuroradiologist. The surgery was performed by a neurosurgeon. In five studies, 
the department of neuroradiology was situated in a university hospital (Anderson et al., 
2006, Beecher-Schwartz et al., 1998; Korogi et al., 1995; Meaney et al., 1995; Voros et al., 
2001) for the department of neurosurgery this was the case in four studies (Anderson et 
al., 2006, Boecher-Schwartz et al., 1998; Korogi et al., 1995; Voros et al., 2001). Patients 
with TN or patients with TN referred for surgery were included (Anderson et al., 2006; 
Benes et al., 2005; Boecher-Schwartz et al., 1998; Fukuda et al., 2006; Korogi et al., 1995; 
Meaney et al., 1995; Patel et al., 2003; Voros et al., 2001 ). When interpreting the MRA's, 
the neuroradiologist was blinded in four studies (i.e., with regard to the clinical infor­
mation (Korogi et al., 1995; Patel et al., 2003) or with regard to which side was affected 
(Anderson et al., 2006; Benes et al., 2005), while in the other four studies no information 
about the blinding of the neuroradiologist was provided Beecher-Schwartz et al., 1998; 
30 
Fukuda et al., 2006; Meaney et al., 1995; Voros et al., 2001 ). The neurosurgeon was aware 
of the MRA :findings in four cases (Anderson et al., 2006; Fukuda et al., 2006; Meaney et 
al., 1995; Patel et al., 2003 ), while the other studies (Benes et al., 2005; Boecher-Schwartz 
et al., 1998; Korogi et al., 1995; Voros et al., 2001)  did not provide information about the 
blinding of the neurosurgeon. In the all investigations, it remained unclear how long after 
the MRA assessment surgery took place. In none of these studies, clear inclusion criteria 
were reported. 
Three studies reported the diagnostic value of magnetic resonance imaging (MRI) in 
temporomandibular joint (TMJ) arthralgia (Murakami et al., 1996; Ohlman et al., 2006; 
Schaefer et al., 2001). In one of these studies, the validity of different pain pressure 
thresholds was also studied (Schaefer et al., 2001 )  Details are listed in table 4. The studies 
were all performed in a university setting. Patients seeking treatment for their TMD were 
first diagnosed using the Research Diagnostic Criteria for Temporomandibular Disor­
ders (RDC/TMD) (Ohlman et al., 2006) or diagnosed with closed lock (Murakami et al., 
1996) and thereafter MRI was performed and blindly interpreted. In Schaefer's study, pa­
tients with unilateral or bilateral TMJ disc displacement with reduction, according to the 
RDC/TMD, and meeting the criteria for arthralgia, were included. MRI's were studied 
for the presence of disc displacement with or without reduction, osteaoarthritis and joint 
effusion. Time between reference test and index test was appropriate (i.e. short enough 
to prevent the targeted disease from changing clinical features) in this study (Schaefer et 
al., 2001). 
Konan and co-workers studied a bite test for identifying whether pain in the TMJ region 
is of muscular or articular origin (Konan et al., 2003 ). Patients with temporomandibular 
disorders were included and patients had to bite on a wedge on the painful as well as on 
the non-painful side. When this test causes temporomandibular pain on the ipsilateral 
side, the pain was interpreted as being of muscular origin whereas contralateral TMJ pain 
would suggest a joint problem. The proposed origin of pain was blindly compared with 
possible articular changes on MRI's, i.e. joint space narrowing, retrusion of the mandibu­
lar condyle and bony signs of joint degeneration (Konan et al., 2003). 
Zuniga and co-workers performed neurophysiological tests in patients with either al­
veolar nerve or infraoribtal nerve deficits (Zuniga et al., 1998). A combination of differ­
ent neurophysiologic test :findings was related to the surgical :findings. Zuniga's study 
included patients from three academic and two peripheral oral and maxilofacial surgery 
practices. Patients with a neurosensory complaint in the distribution of either inferior al­
veolar nerve or lingual nerve injuries were included. Based on an algorithm using a set of 
sensory tests for the inferior alveolar nerve or the lingual nerve, sensory impairment was 
scored being: normal, mild, moderate, severe or complete. The surgical :findings were cat­
egorized as: normal/intact, compressed/intact, neuroma-in-continuity, partial transec­
tion and complete transection. Test and surgical :findings were compared; no information 
was given about the blinding procedure. 
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Cisneros-Cabello and colleague studied the diagnostic value of pain complaints and 
symptoms and pulpal tests in patients with pulpal problems, i.e. patients in need for 
endodontic treatment (Cisneros-Cabello and Segura-Egea, 2005). In a university setting, 
they included patients in need of endodontic treatment because of pulpal pathosis. Pain 
was assessed based on the history and after several thermal and provocative tests. Hereaf­
ter, pulps were removed and prepared for histology. Using developed criteria (Selzer and 
Bender, 1990) the investigators classified patients histopathologically in the following 
diagnostic categories: intact noninflamed pulp, atrophic pulp, acute pulpitis, transitional 
stage of pulpitis, chronic pulpitis, total pulp necrosis, and acute pulpitis superimposed on 
a chronic pulpitis. The authors distinguished treatable (reversible) pulp status from un­
treatable pulp (irreversible) status (pulpitis cases) and compared pain complaints with the 
histopathological diagnosis. The specificity and sensitivity of the different complaints 
and tests are listed in table 5. No information concerning blinding procedures was pro­
vided. Whether the time between clinical diagnosis and histopathological diagnosis was 
sufficient, as well as the selection criteria for eligible patients remained unclear. 
To study the validity of intra-articular tempromandibular joint pain, patients clinically 
diagnosed with articular pain received both placebo and anaesthesia in a cross-over dou­
ble blind fashion (Tjakkes et al., 2007) in the oral and maxilofacial surgery department 
of a university hospital. Patients with preauricular pain, clinically diagnosed using the 
RDC/TMD with articular TMJ pain, were included. Physician and patients were blinded 
to the injected solutions. Pain and maximal mouth opening (MMO) were measured be­
fore and after anesthesia and placebo injections and differences were analyzed. Pain was 
significantly more increased after anesthesia compared to placebo injection. No differ­
ences were found between the two substances concerning MMO. 
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Discussion 
This study aimed at identifying and appraising the evidence-base for diagnostic tests 
for orofacial pain. For the identification of articles on the subject, terms were collected 
for pain in the orofacial region. Furthermore, a search string developed for systematic 
reviews for diagnostic accuracy was used (Deville et al., 2002). To include diagnostic 
studies performed in a randomized clinical trial, a search string for RCT's was used ad­
ditionally (Glanville et al., 2002). Although our initial search resulted in numerous stud­
ies, only minority remained, when methodological criteria were applied. After applying 
criteria for quality assessment, only 15 studies fulfilled more than 7 of 14 QUADAS 
criteria. The QUADAS criteria were developed to enhance systematic quality assessment 
for the use in systematic reviews of diagnostic accuracy studies (Whiting et al., 2003 ). 
When studies are appraised in reviews, not only should the test performance (which 
includes a test's properties like sensitivity, specificity, positive and negative predicative 
values) be described; but also the methodological quality of these studies. Items included 
in the QUADAS are the result of a Delphi procedure. The 14 items relate to methodo­
logical facets of a study. From a list with potentially relevant items, eventually 14 items 
remained for inclusion in the list. This list does not corporate a quality score. As this 
review includes different types of orofacial pain and different types of diagnostic studies, 
it seemed unfair to introduce a quality score that is applied to all the different types of 
studies. However, to include studies which are potentially of good quality, we decided 
that at least 8 items (more than half) should be answered affirmatively. This cut-off point 
has also been used by other authors in their reviews (Graaf de et al., 2006; Seghal et al., 
2007). As a consequence, studies that could have been of good quality but without an 
adequate report of these different aspects of quality, have not been included in our study. 
Interestingly, the majority of the included studies concerned MRA findings versus clini­
cal findings in trigeminal neuralgia. This may be due to the fact that the diagnosis of 
trigeminal neuralgia is clearly described by the current classification systems (Merskey 
and Bogduk, 1994; Olesen, 2004 ). Moreover, the incidence of this disease makes clini­
cal trials easier to conduct than trials in rare conditions. The etiology is often sought 
in compression of the nervus trigeminus. This may relatively easy be demonstrated by 
neurosurgery. Presurgical images may be compared by surgical findings, which serve 
as the gold standard. The sensitivities and specificities of the included trigeminal neu­
ralgia studies are mostly moderate to high, when studied in different study population 
sizes. This seems to justify the use of MRA in patients that are clinically diagnosed with 
trigeminal neuralgia for the detection of vascular compression. Thereafter, surgery aim­
ing at decompression may alleviate the symptoms. In addition, MRA in patients with 
trigeminal neuralgia caused due to other causes than compression, e.g. a tumor or multi­
ple sclerosis, can provide the clinician with relevant diagnostic information. 
Another diagnostic test that has been reported was MRI in diagnosing temporoman­
dibular disorders (Murakami et al., 1996; Ohlman et al., 2006; Schaefer et al., 2001). All 
studies specifically focused on the use of MRI in diagnosing TMJ arthralgia. 
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Table 3. Study design details of included studies 
Patient group Test contrast 
Korogi et al. 1 995 TN 3D TOF M RA gadolinium 
Meaney et al. 1 995 TN MRTA FISP 3D gadolinium 
Boecher-Schwartz at a l .  1 998 TN MRA 3D MPFFES gadolinium 
Voros et a l .  2001 
Fukuda et al . 2003 
Patel et al. 2003 
Benes et al. 2005 
Anderson. 2006 
Murakami et al. 1 996 
Schaefer et al . 2001 
Ohlmann et al. 2006 
Tjakkes et al . 2006 




Cisneros-Cabello et al . 2005 
Zuniga et a l .  1 998 
(IAN) 




























3D TOF MRA 
MRTA (20) 
MRA 3D FFE 
3D FSPGR 






pain compla ints/ 
pulpal tests 
neurosensory tests 






magnetic resonance tomographic angiography 
three-dimensional fast field-echo 
three-dimensional magnetisation prepared fast field-echo sequence 
three-dimensional fast imaging with steady-state precession 
three-dimensional time-of-flight magnetic resonance angiography 










clirica l  (closed lock) 
clinical (RDC/TM D) 
clin ical (RDC/TMD) 













J D:  
N N control sens 
1 6  75 
50 96 
27 88.5 
172 97.6  




1 9  53 
1 4  1 6  85 
68 21 4 32 




250 see table 4 
1 30 60.0 
1 00.0 
three-dimensional fast spoiled gradient-echo 

















38 .7  
77.8 
5.4 
Research Diagnostic Criteria for Temporomandibular Disorders 
computed tomography 
cross-over study design 
inferior alveolar nerve 
lingual nerve 
joint space narrowing 
mandibular retrusion 
signs of joint degeneration 
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Table 5. Specificity and sensitivity of different patient complaints in the diagnosis of untreatable 
pulpal status. (adapted from Cisneros-Cabello et al . 2005) 
p n old s 1m I 28.6 1 00.0 
Pa n uh 97.6 22.2 
Pa , o we t stimuli 95.2 22 .2 
P n fl mg 73.8 27.8 
Pain on lying do n 90.5 27.8 
Pai'l or palpation 97.6 5.6 
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Ohlmann (Ohlman et al., 2006) studied whether MRI findings (disc displacement, osteo­
arthritis, and joint effusion) could predict TMJ pain, diagnosed using the RCD/TMD. 
The authors found no relationship between the MRI diagnosis and TMJ arthralgia. 
However, apart from the clinical and MRI findings, authors used different question­
naires to assess somatisation, jaw disability, and psychological health. Outcomes of this 
assessment were also included in the performed regression analysis. However, inserting 
more variables in a regression analysis influences which and how many predictors are 
eventually found. Taking into account the low to moderate sensitivities and specificities, 
it is disputable whether the costs of an MRI as well as the waiting list justify the use of 
an MRI in diagnosing arthralgia. 
The use of the Krogh-Poulsen test, consisting of biting on a wedge on one side, was stud­
ied by Konan and co-workers (Konan et al., 2003). When joint pain was detected using 
the test, the authors mentioned that radiographic CT showed joint involvement in all 
of these patients. When the test suggested a muscular origin of the pain, 70% of the CT 
scans did not show any abnormality. The authors concluded that these results justify the 
use of this test in determining the origin of temporomandibular pain, which is debatable 
as muscular pain may be accompanied by a damaged but non-painful joint, and a painful 
joint may show no lesions on the CT. Moreover, pain cannot be seen on a CT. Therefore, 
the clinical validity of the authors' conclusions are dubious and the diagnostic value of 
this test is uncertain. 
To study the accuracy of neurosensory testing (NST) in diagnosing trigeminal nerve 
injuries, neurosensory findings in patients with either inferior alveolar or lingual nerve 
injuries were compared with surgical findings (Zuniga et al., 1998). Although the execu­
tion of the study seemed sound, no information could be retrieved concerning the time 
between NST and surgical findings, which could have hampered the results. Neurosen­
sory signs may change over time. For accurate findings and subsequent interpretation, 
to prevent change of neurosensory signs, the time between NST and surgery should 
therefore be minimized. The NST can be of help in staging the neurological deficit, but 
is not suitable for purely diagnostic use. 
In tooth pain, diagnostic tests are used in order to assess the pulpal condition. Cisneros­
Cabello and colleague (Cisneros-Cabello and Segura-Egea, 2005) studied the relation­
ship between pain complaints, pulpal tests, and the histopathological diagnosis. There­
after the sensitivity and specificity as well as reliability of the pain complaints in the 
untreatable (i.e. irreversible) pulp status were calculated. The authors defined reliability 
as the percentage of true results (in addition to true positives and true negatives). To our 
opinion, in this case the reliability should refer to the consistency of test result from a 
test, i.e. test-retest reliability. To distinguish between reversible and irreversible pulp sta­
tus seems reasonable, as it relates to the indication of (invasive) treatment. The authors 
discuss a few significant correlations between pulp status and pain complaints and their 
corresponding sensitivity and specificity. However, no single pain complaint showed 
both satisfactory sensitivity and specificity. Although omitted, this offered the authors 
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an opportunity to combine different complaints as diagnostic tests, in order to suggest 
practical guidelines. 
To study the effect of injection of an anesthetic solution in the temporomandibular joint 
as a diagnostic test, Tjakkes and colleagues (Tjakkes et al., 2007) studied the effect on 
pain and maximal mouth opening ability in a cross-over placebo controlled trial. No 
differences were found with respect to mouth opening between the two solutions. The 
authors did find a difference in pain relieve between anesthesia and placebo. However, 
on average the pain was not completely reduced after anesthesia. Although clinical ex­
amination lead to the conclusion that the pain was of articular origin, nearby painful ( e.g. 
muscular) structures may have also been responsible for the pain felt in the temporoman­
dibular joint region. This may have had an effect of the (lack of) pain diminishing effect 
of the anesthestic solution in some cases. Therefore the results of diagnostic anesthesia 
should be interpreted carefully before any (irreversible) intervention is considered. 
In most of the studies, tests are performed in patients who have been diagnosed or in­
cluded based on clinical criteria from existing classification systems; patients with clear 
symptoms are used. This will have an effect on the diagnostic performance of the test. 
Test outcomes may be less obvious or harder to interpret in patients in other (i.e. less 
severe) stages of the disease. This affects the generalizability of the study outcomes and 
also explains the lack of studies concerning less obvious orofacial pains. 
Our results indicate that, when applying a tool which assesses the quality of diagnostic 
research, only a minority of the studies are of sufficient methodological quality. This is 
remarkable, as orofacial pain and accompanying diagnostic tests are common in dental 
and medical practice. Orofacial pains that are well defined and can be easily diagnosed 
based on clinical examination have been studied well and are of sufficient quality. Less 
well defined pains, which merely refer to chronic idiopathic orofacial pains, do not seem 
to be captured easily within a (single) diagnostic test. In chronic orofacial pain, which 
can hardly be differentiated using standard assessment tools, there is still need for new 
diagnostic tools that differentiate between different pain categories, which may provide 
directions for subsequent treatment. 
In theory, the process leading to a diagnosis seems relatively easy, which in a majority 
of (acute) pain problems may also be the case. In complex cases, where the initial diag­
nostic process (including proper history taking and clinical examination) has not yet led 
to a diagnosis, there is an urgent need for more diagnostic information. This hides the 
danger of overestimating the information obtained from the performed test. Although 
attempts have been made to enhance the diagnostic process and to expand the diagnostic 
possibilities, a larger diagnostic armamentarium is warranted in order to be able to dif­
ferentiate between different diagnostic subgroups in chronic idiopathic orofacial pain 
patients. Once this differentiation can be validly and reliably made, this may enhance the 
subsequent treatment. 
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The effect of intra-articular inJection of 
ultracain in the temporomandibular joint in 
patients with pre-auricular pain. 
A randomized prospective double blind 
placebo controlled crossover study 
This chapter is based on: The effect of intra-articular injection of ultracain in the temporoman­
dibular joint in patients with pre-auricular pain. A randomized prospective double blind placebo 
controlled crossover study. Tjakkes GH, Ten Vergert EM, de Bont LGM, Stegenga B, published in 
The Clinical Journal of Pain, 2007: 23:233-236. 

Abstract 
Aims: To evaluate the distinguishing ability of intra-articular anaesthesia from placebo in 
orofacial pain patients with pain located in the temporomandibular joint (TMJ) region, 
aiming at a validation of intra-articular anaesthesia injection as a diagnostic test of pain 
in the TMJ region. 
Materials and methods: A randomized prospective double blind placebo-controlled 
crossover study was conducted among 19 patients (18 females, 1 male) with pain in the 
TMJ region. The short-term effects of intra-articular ultracain and saline injections on 
pain and maximum mouth opening (MMO) were measured and analysed. 
Results: Compared to placebo injections, a statistically significant difference in pain 
scores was found after intra-articular injection of a local anaesthetic as far as Visual Ana­
logue Scale scores were concerned. The MMO scores did however not differ between the 
two groups. 
Discussion: TMJ injection with local anaesthesia leads to decrease of pain in patients 
with preauricular pain. In order to establish the source of pain, injection of a local an­
aesthetic in the TMJ may be used as a diagnostic tool. However, the results of diagnostic 
injections should still be interpreted cautiously. 
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Introduction 
Temporomandibular disorders (TMD) comprise disorders of the temporomandibular 
joint (TMJ) and its associated muscles. Currently, pain conditions in general and TMD 
in particular are classified according to a bi-axial system. Axis I includes physical condi­
tions (the 'disease'), while axis II involves the pain-related disability and psychological 
status (the 'illness'). According to the research diagnostic criteria (RDC), axis I classifica­
tion consists of three subgroups, i.e., muscle disorders, disc displacements and a group 
labelled "Arthralgia, arthritis and arthrosis". (Dworkin and Le Resche, 1992) These sub­
groups are not mutually exclusive, but the specific disorders within the subgroups are. 
It has been suggested to classify the specific TMD in accordance with the classification 
of other synovial joints, based on intra-articular pathologic processes. (Stegenga, 1991, 
1996) The articular TMD consist of disorders of the joint itself (e.g. osteoarthrosis, in­
ternal derangement, intra-articular fractures, infections, tumours and inflammatory dis­
orders). The non-articular TMD comprise disorders of the muscles associated with the 
TMJ, among other disorders. This classification also recognizes that the TMJ as well as 
its associated muscles may be involved in generalized disorders, such as rheumatoid ar­
thritis, fibromyalgia, or polymyalgia rheumatica. 
Pain perceived in the temporomandibular joint area may originate from the joint proper 
as well as from other nearby and distant structures. A thorough history, complete physi­
cal and radiographic examination usually lead to a diagnosis, although sometimes further 
diagnostic tests are needed. Okeson has defined primary pain as pain that emanates from 
a structure that hurts, whereas in secondary pain the site of pain differs from the true 
location of its source. (Okeson, 1995) Additional clinical diagnostic tests (based on the 
response to provocation) and analgesic blockade with local anaesthesia could assist in 
establishing a diagnosis. 
A positive response to a local anaesthetic (i.e. diminishing the pain) is frequently used as 
a justification for further (nonsurgical and surgical) therapy. It may also be used as an in­
clusion criterion in ( experimental) studies. Despite these - sometimes far-reaching - con­
sequences, the validity of such a diagnostic test has not been formally established. The 
aim of this study was to evaluate the distinguishing ability of intra-articular anaesthesia 
from placebo in orofacial pain patients with pain located in the TMJ region. The hypoth­
esis whether intra-articular local anesthesia (ultracain) relieves pain more and improves 
the maximum mouth opening (MMO) to a greater extent than placebo in patients with 
pre auricular pain, was tested. 
The effect of intra-articular injection of ultracain in the temporomandibular joint in patients with 
pre-auricular pain. A randomized prospective double blind placebo controlled crossover study 
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Materia ls and Methods 
Patients 
Patients meeting the criteria of Axis 1 of the type III group of the research diagnostic 
criteria based on clinical assessment were subjects of this study. This group of diagno­
ses consists of "arthralgia, osteoarthritis and osteoarthrosis" of the TMJ. (For details 
see Dworkin and LeResche, 1992). Consecutive patients with painful types of above 
mentioned TMD referred to the Orofacial Pain section of the Department of Oral and 
Maxillofacial Surgery at the University Medical Center Groningen (UMCG) were asked 
to participate in the study. Additional inclusion criteria were: age between 16-65 years, 
presence of subjective mandibular movement restriction and/or function impairment. 
Standard clinical examination, existing of assessing TMJ pain and measurement of func­
tion impairment, patients' subjective complaints were confirmed, in order to be able to 
allocate suitable patients meeting the above mentioned criteria into the study popula­
tion. Patients with predominantly myogenic pain dominating the pain complaints, od­
ontogenous causes of pain such as pericoronitis, or tumours in the orofacial area were 
excluded. To screen the patient's psychological status in a hospital setting the Hospital 
Anxiety and Depression Schedule (HADS) (Zigmond and Snaith, 1983) measuring anxi­
ety (HADS-A) and depression (HADS-D) was used. Eligible patients gave informed 
consent after receiving oral explanation and written information about the study design 
and the specific requirements related to participation of the study. The patients did not 
receive monetary compensation. This study was approved by the Medical Ethical Com­
mittee of the UMCG. 
Study design 
The present study was designed as a prospective randomized double-blind placebo-con­
trolled crossover trial. The (most) painful TMJ of each patient was injected twice. To 
reduce confounding of injections with the order in which they were administered, the 
injections were allocated in a randomized fashion. The washout phase between injections 
with articaine hydrochloride with 1 :200,000 epinephrine (Ultracain D-S; Aventis®, The 
Netherlands) and injections with sterile normal saline or vice versa was two weeks. The 
sequence of injection was randomized. The randomization was performed by computer 
using the randomization function of StatsDirect™. The pharmacy of the UMCG pre­
pared the injection fluids, which were supplied in identical ampules in a coded box. Thus, 
the patient, the clinician who performed the injection, and the clinician who performed 
the assessments were all unaware of which solution was injected. 
In order to prevent possible bias from anaesthetic skin sensation following the injec­
tion with ultracain, all patients were supplied with topical anaesthesia of the skin in the 
preauricular area (lidocain 25 mg / prilocain 25 mg, EMLA®, AstraZeneca, USA) for at 
least 45 minutes. The past and current TMJ pain intensity were assessed (see below). In 
addition, the patients were requested to answer several questionnaires (see below). The 
maximum assisted interincisal distance and the level of pain were measured during the 
clinical examination, immediately preceding (i.e., after 45 minutes of topical anaesthetic 
application) and following the injection. 
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After removal of the EMLA topical anaesthesia, the skin overlying the joint area was 
cleaned and disinfected with a 70% ethanol solution. Subsequently, the upper compart­
ment and capsule of the joint were injected with either 0.5 ml ultracain or 0.5 ml saline. 
During each visit, the patient was carefully monitored with respect to possible side ef­
fects. Also, in case of any problems between or after the two visits, patients could contact 
an independent oral and maxillofacial surgeon. After enrolment of all patients, the blind­
ing code was broken and data were analysed. 
Pain assessments 
TMJ pain intensity was recorded at arrival, after initial MMO measurement, after 45 
minutes with topical anaesthesia, after subsequent MMO measurement, 2 minutes after 
the injection, and after the final MMO measurement (5 minutes after injection). A Visual 
Analogue Scale (VAS) (Price et al., 1983 ), i.e., a 100 mm scale with endpoints designated 
as 'no pain' and 'worst pain imaginable' was used for pain intensity assessment. 
Assessment of movement restriction and function impairment 
The MMO was measured at three occasions, i.e. during the clinical examination, after 
45 minutes of topical anaesthesia immediately before injection, and 5 minutes following 
the injection. The patients were requested to open as wide as possible, after which the 
distance between the upper and lower lateral incisors was measured with a millimetre 
ruler. At each occasion, the MMO was recorded three times. This measurement has been 
found to be highly reliable (intraclass correlation = 0.96) (Dworkin and Le Resche, 1992) 
The patients' mandibular (dys)function was assessed with the Mandibular Function Im­
pairment Questionnaire (MFIQ) (Stegenga et al., 1993b). A Function Impairment Rating 
Score (range 0-5) of mandibular function was calculated, scores O and 1 representing a 
low, scores 2 and 3 a moderate, and scores 4 and 5 a severe level of function impairment. 
Statistical analysis 
Data were analysed using SPSS 12 (SPSS Inc, USA). To check normality of differences in 
VAS and MMO scores before and after ultracain and placebo injection, the Kolmogorov­
Smirnov test was performed. After proof of normality, t-tests for paired samples were 
performed to test the differences between VAS scores and MMO scores after ultracain 
and after placebo injection. HADS and MFIQ scores were presented descriptively. 
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Resu lts 
In total 20 patients were enrolled in this study (19 females and 1 male). Their age ranged 
from 18 to 62 years, with a mean age of 32.5 years (SD=12.0 years). One female patient 
decided to withdraw from the study after the first (in her case placebo) injection for 
personal reasons. 
The mean HADS-A score and the mean HADS-D score was, respectively, 4.6 (SD=3.6) 
and 5.1 (SD=2. 9) on a 0-14 point scale. Both scores were below the range of values in the 
general population (average score of < 7) which indicates no signs of anxiety or depres­
sion in the included patients. The mean function impairment score at the first visit was 
3.5 (SD=l .3) on a 1-5 point scale (i.e., moderate-severe function impairment). 
After the ultracain injection VAS scores in the ultracain group decreased from 65.7 
(SD=22.9) to 52.9 (SD=30.9). The VAS scores after injection with placebo increased from 
57.8 (SD= 21.7) to 62.3 (SD=26.7). Consequently, the mean VAS difference after ult­
racain injection was -12.8 (SD 23.5) and the mean VAS difference after placebo injection 
was 4.5 (SD 15.0). This difference between VAS scores before and after ultracain and 
placebo injections was statistically significant (p= O.Ql 4 ). 
The mean difference in MMO scores before and after ultracain injection and placebo 
injection was, respectively, 2.0 (SD=2.9) and 0.4 (SD=2.9) compared to the situation be­
fore injection. This difference between the MMO score differences of the ultracain and 
placebo group was not statistically significant (p= 0.103) 
50 
Discussion 
Our results show that there is a statistical significant difference in pain scores after injec­
tion with a local anaesthetic compared to the pain scores following a placebo injection. 
The effect of the injection of a local anesthetic may therefore be used as a diagnostic tool 
in the assessment of TMD in order to establish the source of pain. 
For treatment planning, establishing the source of pain in the TMJ region may be vital. 
In patients presenting with preauricular pain, it is important to distinguish articular from 
non-articular sources of pain. Anaesthesia of the joint by injecting a local anaesthetic 
into the intra-articular space is frequently used as a diagnostic tool, but has never been 
validated for that purpose. Effects of intra-articular local anaesthesia injections have been 
studied in other joints. A systematic review of studies about pain relief following intra­
articular local anaesthesia injection compared to no or placebo treatment after arthro­
scopic knee surgery showed that 8 out of 20 studies reported no improved pain relief 
after local anaesthesia injection (M0iniche et al., 1999) . 
In a recent opinion article, the use of intra-articular TMJ anaesthesia injections for the 
use in diagnosing and treating TMJ and myofascial pain was promoted, (DuPont, 2004) 
using a short-acting plain anaesthesia (e.g. 2% lidocaine or 3% carbocaine). If significant 
pain reduction after 10 minutes followed, the TMJ would probably be the source of pain. 
This seems to be an useful method of establishing a diagnosis, however, no evidence for 
the offered statements was offered. Danzig et al. have found significant pain decrease af­
ter intra-articular injection of an anaesthetic solution in the TMJ of patients with persis­
tent TMD. (Danzig et al., 1992) No placebo controlled design was used however, making 
the attribution of pain relief solely to the anaesthetic solution questionable. 
In order to prevent care providers from drawing erroneous conclusions after anaesthetic 
injections, we studied this diagnostic tool in a randomized, double-blind placebo-con­
trolled manner. In other designs, articular injections, of other substances e.g.  opioids, 
have been evaluated, with or without a combination of a local aesthetic. We did not 
study the long term effect of the injections as it was validated for the purpose of an aid 
in the diagnosis of orofacial pain. Normally this diagnostic test will take place in a clini­
cal setting in which the clinician relies on the immediate (early) response of the patient. 
Long-term effects were only taken into account in calculating the period-effect which 
appeared to be negligible. Therefore, long-term effects for this purpose were considered 
as being irrelevant. 
The reduction in VAS scores after anaesthesia injection was found to be relative. This 
may be due to technical factors e.g. varying anatomical structures, different concentra­
tion and volumes of anaesthetic used, or psychological effects. Another reason that may 
have lead to incomplete pain reduction is that for analysis of the value of a diagnostic 
test, one needs to have a golden standard. We included our patients using the diagnostic 
criteria, as mentioned earlier using a standard clinical examination as well as the MFIQ, 
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to ensure that patients with mainly articular pain would participate in our study. This 
means that the inclusion took place without the aid of a golden standard test, as it does 
not exist for these disorders. Therefore, included patients could have had coexisting pain 
problems, e.g. myofascial pain contributed to the TMJ pain and therefore the effect of 
the injections. According to the HADS, our patients showed no signs of psychological 
distress and thus the perceived pain may be considered as being of merely somatic origin. 
Furthermore, incomplete pain relief may also be due to incomplete anaesthesia of the 
responsible nerve endings. By injecting in the TMJ, some parts of the superior branch 
of the auriculotemporal nerve may be left unaffected resulting in inadequate anaesthetic 
effect and may lead occasionally to incorrect conclusions. 
In our study we found no significant difference in maximum mouth opening between the 
above mentioned groups. This may be due to the fact that at every MMO measurement, 
the anatomical limit of mouth opening was achieved and would, therefore, not be influ­
ences by the type of injected solution. 
We have chosen to compare the effects of ultracain with the effects of saline, a placebo, in 
order to be able to judge the effect of the ultracain solely on the based on the anaesthetic 
effect. A positive response to placebo however, does not imply that the patient is malin­
gering, as a placebo response is obtained in approximately 33% of all subjects (Gross, 
1991), although the effect of placebo has not shown to be clinically relevant (Hr6bjarts­
son and G0tzsche, 2006) The suggestion that a pain relieving treatment has been given 
may be sufficient to provide pain reduction. (Fields and Price, 2006) However, in the 
design used in our study patients were informed that they would receive both placebo 
and anaesthesia, indeed in a double blind manner, so this may have led to a reduction of 
the pain diminishing effect of the placebo. Immediate short-time results after diagnos­
tic anaesthesia should not be misinterpreted. As stated above, a pain diminishing effect 
could be due to placebo response. Patients may also be eager to response positive in their 
eagerness to help diagnose their problem or to get treatment. 
In summary, our results suggest that TMJ pain perception after injection of an anaes­
thetic agent does differ from the perception after placebo injection. As an aid in the diag­
nostic process, intra-articular injections may be used, but one should still be cautious in 
interpreting the results. Therefore, we recommend verifying the outcome of diagnostic 
injections at least once before coming to conclusions. 
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Abstract 
Aims: The aim of this study was to evaluate the results of a preliminary intravenous 
diagnostic test. 
Patients: Patients with chronic orofacial pain conditions that could not be unambigu­
ously diagnosed. 
Design: A retrospective evaluation of series of conducted pharmacodiagnostic tests, con­
sisting of the consecutive intravenous administration of drugs. 
Outcome measures: Visual Analogue Scale scores were retrieved from all patients, based 
on which they were classified into different responder groups. 
Results: In total, 46 pain profiles were analysed. Of these, 16 patients (35%) could be 
classified into one or more pain categories, while 30 patients (65%) could not be classi­
fied into any pain category. The pain duration or medication use did not influence the 
classification. 
Conclusion: Based on the results of this retrospective study, it seems that classification 
into subgroups is possible after intravenous testing in a minority of clinically unclassifi­
able patients. In patients where there is a substantial need for additional diagnostic infor­
mation, these results may be of value. Recommendations are made for further research, 
which should include validation in patients with known pain mechanisms. 
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Introduction 
Orofacial pain, referring to pain experienced in the mouth and facial area, is very com­
mon in medical and dental practice (Macfarlane et al., 2002). A median prevalence of 
13% has been described based on epidemiological studies (Macfarlane et al., 2001). Facial 
pains include odontogenic pains, painful diseases of the oral mucosa and salivary glands, 
temporomandibular disorders, and neurological ( e.g. neuralgia) and vascular pains ( e.g. 
temporal arteritis, migraine). The diagnosis of these orofacial pains is usually straight­
forward, the majority being acute or transient in nature. Pain associated with temporo­
mandibular disorders and neurovascular mechanisms may, however, be more persistent 
(Sessle 2000; Israel et al., 2003 ). 
Chronic orofacial pain conditions are often difficult to diagnose and manage. Pains that 
cannot be readily diagnosed are frequently referred to as 'atypical', implying that typi­
cal facial pains have been excluded (Israel et al., 2003 ). In the classification of the Inter­
national Headache Society, a subgroup "persistent idiopathic facial pain" exists, which 
includes atypical facial pain and atypical odontalgia (Headache Classification Subcom­
mittee of the International Headache Society, 2004 ). Others proposed the term "chronic 
idiopathic orofacial pain" which should include atypical facial pain, atypical odontalgia, 
masticatory pain, temporomandibular joint disorder pain and oral dysesthesia (Woda 
and Pionchon, 2000). The term 'atypical orofacial pain' has also been suggested as a di­
agnostic term, describing an ongoing, continuous, more or less constant intense chronic 
pain disorder, frequently of burning quality. Atypical tooth pain is sometimes referred 
to as "atypical odontalgia", and when the oral mucosa is involved, terms like "oral dys­
esthesia" and "burning mouth syndrome" are commonly used. Characteristically, an 
obvious nociceptive substrate is absent Qacobs et al., 2002). Psychological problems are 
associated in these forms of pain, although whether these problems are causative or sec­
ondary is still subject of debate (Baad- Hansen, 2008). Persistent idiopathic facial pain is 
currently thought to be neuropathic in nature, especially when the pain is accompanied 
by paresthesia (Baad- Hansen, 2008). It has also been suggested to be maintained by au­
tonomic sympathic influences. 
Patients with chronic orofacial pain frequently undergo numerous dental procedures 
that f?-il to eliminate their symptoms (Milam, 1997). Interventions that cause tissue dam­
age, such as endodontic therapy and surgery, may even exacerbate and perpetuate pain 
symptoms, causing these patients to use (high doses of) analgesics, sometimes even more 
than considered safe, as well as antidepressants and anxiolytics Q acobs et al., 2002). Thus, 
patients with chronic orofacial pain are commonly characterized by multiple diagnoses 
and inadequate management by multiple disciplines (Israel et al., 2003). 
When the patient's daily life becomes dictated by pain, psychological changes and re­
strictions in lifestyle result in limited capabilities. Therefore, there is a need for early 
detection of the mechanism(s) underlying the pain state as a basis for rational treatment. 
As stated by Woolf: "Perhaps, in the future, when the analgesic armamentarium includes 
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drugs that act on specific mechanisms, it might be possible to judge patient response to 
these therapies as diagnostic of underlying mechanisms " (Woolf et al., 1998). The aim of 
this pilot study was to evaluate the result of a preliminary intravenous diagnostic test 
based on the response of intravenous administration of different pharmacological probes 
as possible initiative to distinguish between different pain mechanisms in chronic orofa­
cial pain patients. 
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Material and methods 
Patients 
Data for this study were retrieved from the files of consecutive patients with chronic 
orofacial pain with an ambiguous diagnosis who had attended the Pain Clinic of the 
University Medical Center Groningen (UMCG) between February 1998 and January 
2004 to receive a pharmacodiagnostic test (PDT). Standard examination included his­
tory taking with intra- and extra-oral examination. When a dental origin of the pain was 
suspected, periodontal probing, pulp vitality testing (combining chlorethyl as cold test 
and hot gutta-percha as warmth test applied to suspicious teeth) and tooth percussion 
test were performed, diagnostic local anesthesia was given and dental radiographs were 
taken. When mucosal problems were suspected, periodontal probing was performed, 
if applicable, diagnostic local anesthesia was given and radiographs were taken. When 
temporomandibular disorders were suspected, a functional examination was performed, 
radiographs were taken and if applicable (intra-articular or intramuscular) local anes­
thesia was performed. These performed diagnostic tests were inconclusive for adequate 
diagnosis. 
A total of 49 patients were tested ( 46 females and 3 males; mean age at the time of phar­
macological testing 43.7 years, SD=l 1.4). The average pain duration was 8.0 yrs (SD= 
6.2), ranging from 1 to 25 years. Of the 49 patients, eleven did not use any medication. 
Medication used by the other 38 patients varied from paracetamol and NSAID's to opi­
oids and combinations of medication. In table 1, information on the types of used medi­
cation is provided. 
Procedure 
To perform the pharmacological test, patients were hospitalized for one day in the 
UM CG. The test was performed based on a standardized protocol. The following agents 
were administered intravenously in fixed doses and in a specific order with a ten-minute 
interval: 
Saline (0.9%) 
Phentolamine 5 mg in 5 min 
Saline (0.9%) 1 0 ml 
Thiopental 50 mg in 3 min 
Saline (0.9° 0) 1 0 ml 
Fentanyl 50 µg 
Naloxone 400 µg 
Saline (0.9°0) 1 0  ml 
Lidocaine titration 200 mg in 60 min 
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Pain ratings were taken before the test and after each drug or placebo delivery at fixed 
intervals. Pain intensity was measured using a 100 mm Visual Analogue Scale (VAS) [Pri­
ceet al., 1983), the endpoints of which are designated as 'no pain' and 'worst pain imagi­
nable'. In addition, possible side effects occurring during this test were monitored. 
Criteria for pharmacological classification of the patients 
Pain changes were measured by comparing the baseline VAS with the VAS score after 
each administration. In our study, patients were classified as 
placebo responders when 33cc. or more decrease of pain occurred after at least two placebo 
administrations 
phentolamine responders, thiopental responders or lidocaine responders when there was 33° ·� 
or more decrease of pain after phentolamine, thiopental responders or lidocaine administration, 
respectively, without any or with minimal effect in response to placebo administration. 
opoid responders when they showed 33Q o  or more decrease of pain after fentanyl administra­
tion and increase of pain after subsequent naloxone administration, with no or minimal affect on 
p lacebo administration. 
When a decrease of pain of 33°,o or more was measured in two or more active agents, patients 
were classified into multiple groups. Patients who showed a response of less than 33% to any of 
the agents administered were classified as non responders. 
To study whether pain medication influenced the classification, patients who used medi­
cation were compared with the group without medication. In addition, to study whether 
classification was influenced by pain duration, the percentage of non responders for dif­
ferent pain durations was calculated. An analysis of variance for repeated measures was 
performed to study the stability of all placebo injections. 
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Table 1 .  Types of medication used with number of patients 
Paracetamol 5 
Paracetamol/ codeine 4 
_--:,____: 
Paracetamol /anti convulsant 5 
Non steroidal anti inflammatory drug (NSAID) 4 
.::-: 
NSAID / tricyclic antidepressants 3 
NSAIQ /  paracetamol 2 - � ·-
NSAID / anticonvulsant 3 
-- I -
Tricyclic antidepressants 4 




Table 2. Types en numbers of responders 









Placebo- thiopental -fentanyl- lidocaine 
Thiopental -fentanyl-phentolamine-lidocaine 
Placebo-fentanyl-phentolamine- thiopental - lidocaine 



























Figure 1 .  Average VAS scores at baseline and after placebo infusions with 95% confidence interval 
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Results 
All included patients were tested without any notable side effects. VAS-scores from the 
patients were analysed, combining the responses to intravenous pharmacological agents 
with the above-mentioned criteria. When applying the above-mentioned criteria and be­
cause of missing baseline VAS scores of three patients, 46 VAS-scores were available. Six­
teen out of these 46 patients could be classified as responder to one or more agents. The 
remaining 30 patients could not be designated as responder. Data are specified in table 2. 
No significant differences were found when the VAS scores following all placebo injec­
tions were compared within all subjects (p=0.95). Average VAS scores after placebo infu­
sions are shown in figure 1. Subsequently, figure 2 shows VAS scores after drug infusions. 
The percentage of non responders in the available pain duration ages is shown in figure 3. 
Non responsiveness occurred in patients with pain duration varying from 1 year to 21 
years. 
Of the 'non medication' group, four out of 11 patients could be classified (36% ). Of the 
patients who did consume pain medication twelve could be classified (34%). Types of 
used medication are described in table 1. 
Figure 3. Percentage non responders per available pain duration group 
Percentage non responders in available pain duration (year) 
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Discussion 
In the management of chronic pain patients, history taking and physical examination 
will largely contribute to the establishment of a diagnosis. However, when this is not 
sufficient and additional information is necessary, other means of differentiation are de­
sired. The current study attempted to differentiate chronic pain patients (who could not 
be differentiated by means of history taking, physical information and other additional 
diagnostic tests), based on the response on a battery of pharmacological agents . In this 
study, 16 patients (35%) could be classified into one or more responder groups. The 
majority (65%), however, could not be classified when using the baseline VAS as refer­
ence for classification. Although the percentage of responders may seem disappointing, 
in this category of patients any additional diagnostic information is of beneficial value. 
However, due to the retrospective manner of retrieving data, potentially important data, 
e.g. baseline psychometric measures, were not available in most cases . Baseline data, such 
as the duration of the pain could be determined for all patients, but did not influence the 
classification of these patients, as is shown in figure 3. 
The responses after administration of the different pharmacological agents have been 
suggested to be used to determine different pain generating pathophysiological mecha­
nisms (Sorensen et al., 1995; Sorensen et al., 1996; Sorensen et al., 1997; Alvarado, 2006) 
For instance, fentanyl has been suggested to identify nociceptive pain (Gowing et al., 
2003) . Fentanyl is a morphine derivate and is 80 to 100 times more potent as morphine 
(Poklis, 1995 Gowing et al., 2003; Brunton et al., 2006) . Fentanyl produces a peak anal­
gesia after 5 minutes (Brunton et al., 2006 ) .  The effect of fentanyl should be reversed by 
its antagonist naloxone to confirm opioid responsiveness, as naloxone antagonizes the 
toxic and clinical effect of opiates (Brunton et al ., 2006 ) .  In a recent review, studies report 
mixed results concerning the effect of opioids on neuropathic pain (Brunton et al., 2006 ) .  
In particular, fentanyl has been shown to  relieve non-cancer neuropathic pain, although 
very short-time (immediate) effects remain unclear (Dellemijn and Vanneste, 1997) . 
In neuropathic pain, the nervous system itself has changed either structurally or func­
tionally, and lidocaine has been suggested to eliminate this type of pain (Marchettini et 
al., 1992; Wallace et al., 1996; Meyerson et al., 1997; Yamamoto et al., 1997; Challapalli et 
al., 2006). In previous trials, different dosages have been used e.g .  100 mg per patient or 
individual dosage varying from 1 to 5 mg/kg, either with or without a preceding bolus 
(Challapalli et al., 2006, Mao and Chen, 2000). In a group of postherpetic neuralgia, no 
additional benefits were found when 5 mg/kg was used instead of 1 mg/kg (Baranowski 
et al., 1999) . Systemic lidocaine has shown to have no effect on nociceptive pain (Petersen 
and Rowbotham, 2000; Dirks et al., 2000). 
Occasionally, the nervous system may be activated by autonomous input (i.e., sympa­
thetically maintained pain) . Phentolamine specifically affects this mechanism (Raja et al., 
1991; Arner 1991) and thus is the likely drug to selectively modify this pain mechanism. 
It is a short-acting, competitive alpha adrenergic receptor antagonist, with tachycardia 
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and vasodilatation as clinical effects (Brunton et al., 2006 ). This sympathicolytic pro­
cedure was able to predict the effect of subsequent intravenous regional guanethidine 
treatment with set dosages varying from 5-15 mg (Arner. 1991). Finally, thiopental, a 
(ultra) short acting barbiturate, is used in a low dose, aiming at centrally mediated pain 
(Dickinson et al., 2002). It rapidly achieves a therapeutic plasma concentration (Brunton 
et al., 2006 ). 
Although all the aforementioned mechanisms have been suggested to be affected by 
specific drugs, caution must be taken when interpreting the short-term effects of the 
intravenous administration of these drugs. When patients respond to agents, the precise 
clinical consequence remains unclear. Are all suggested mechanisms involved or do these 
patients respond to any intervention? Until more scientific data are obtained with regard 
to these effects, it seems more appropriate to refer to the pain relieving effects as "drug 
response" rather than influencing specific pain mechanisms. 
As the test is done with :fixed low doses, again caution must be taken in interpreting the 
tests' results. These doses may be too low in certain patients to attain a specific effect. 
In addition, it is not possible to rule out the possibility of carry-over effects, although 
the VAS scores following all placebo injections remained stable, indicating a similar VAS 
level prior to all provided drugs and thus suggesting no notable residual effects. Further 
research should provide further justification for this type of mechanism-based approach 
in chronic orofacial pain patients. 
Previous studies have used other regiments to come to individual dosages, such as cal­
culation of dosages using the bodyweight, or titration until the desired effect (i.e., pain relief), undesired effects (e.g. side effects) or a maximum dosage was achieved. However, 
titration leads to a longer duration of the test, which may lead to lack of compliance and 
increased costs. Also, interindividual differences, in e.g. physiology, likely lead to differ­
ent reactions after and different effects of drug infusion. This may plea for individualisa­
tion of the dosages using the patients' bodyweight. In future designs, it may therefore be appropriate to start with a standardized test, which may be followed, if necessary, by an 
individually tailored test. This individual test could be an elaboration of potential effec­
tive drugs, which are subsequently titrated until (un)desired effects are achieved. 
To study whether patients' current medication use modified the test outcome, we com­
pared the patients who did not use any medication with the patients who did. In both 
groups, equal proportions of patients could be classified into responder groups. So ap­
parently, medication use did not influence the ability to classify patients. Relative differ­
ences in pain were measured in this test and outcomes may be indicative of a pharma­
cological approach, which is additional to the current medication used. When a critical 
reappraisal of current pain medication is warranted, one should refrain from medication 
(if possible) before testing these patients. 
We used a cut-off point of 33% pain relief as being sufficient to provide insight in the 
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underlying pain mechanism, as on a numeric scale this reduction was found to be as­
sociated with a "much better" change (Salaffi et al., 2004; Farrar et al., 2000) . Farrar and 
co-workers also proposed the percentage of 33% rather than the more often used 50% in 
order to prevent underestimation of research results, especially when this cut-off point is 
used to obtain insight in the effect of a diagnostic test rather than the efficacy of a treat­
ment (Farrar et al., 2000) . 
The current design of the test was chosen based on face validity (i.e., does the test in­
tend to measure what we want?) . To study the construct validity of this pharmacological 
test for chronic orofacial pain for the purpose of differentiating between different pain 
mechanisms, patients diagnosed with only nociceptive pain, only neuropathic pain, and 
only sympathetically maintained pain, preferably in the orofacial region, should be used. 
Using a control group without pain would complete the validation (by assessing whether 
pain free persons perceive pain after injections), although this might be inappropriate 
from an ethical point of view. In addition, the pharmacological test should be performed 
twice in a subset of patients to assess intra-individual reliability and consistency. 
In summary, with pharmacological testing, disentangling complex chronic orofacial pain 
problems seems possible in at least a subset of patients. In patients with ambiguous diag­
noses, even after thorough examination and/ or previous unsuccessful treatment, subtle 
directions for treatment planning may potentially be provided by this way of testing. 
Future research should, however, establish the validity and reliability and clinical conse­
quences of the outcomes of this seemingly promising diagnostic tool. 
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The effect of an intravenous diagnostic test 
on nociceptive, neuropathic 
and sympathetically maintained pain 
This chapter is based on: The effect of an intravenous diagnostic test on nociceptive, neuropathic and 
sympathetically maintained pain. Tjakkes CHE. Huddleston Slater ]JR, Van \Vijhe M, De Bont 
LG it, Stegenga B. Submitted. 

Abstract 
Aims: The purpose of this study was to assess the distinguishing ability of a pharma­
codiagnostic test on participants that were clinically diagnosed as having nociceptive, 
neuropathic, or sympathetically maintained pain (SMP). 
Materials and Methods: The response to the consecutive intravenous administration of 
fentanyl, naloxone, phentolamine, lidocaine, alternated with saline, was tested for the 
three groups of participants, i.e. patients with nociceptive pain, neuropathic pain, and 
SMP. The responses of the patients to each of the agents were measured using Visual 
Analogue Scale scores. 
Results: 14 nociceptive pain patients; 4 sympathetically maintained pain patients and 
10 neuropathic pain patients underwent the test. Using multilevel modelling, the three 
clinically differing pain groups could be identified. Age appeared to be a confounder 
with regard to the primary outcome measure, and the coefficients were corrected for this 
confounding. 
Discussion: Pharmacological distinction between three different pain mechanisms seems 
possible using the present pharmacological test. These results may contribute to the di­
agnostic process in chronic ( orofacial) pain patients, where there is a great need for ad­
ditional diagnostic information. In these patients, pharmacological testing could bring 
additional insight in occurring pain mechanisms. 
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Introduction 
Diagnosing orofacial pain conditions often appears to be a difficult task for the clinician. 
To establish a diagnosis, various strategies are currently used (figure 1). Most frequently, 
the site of pain perception is used as a first indication for a possible diagnosis. If the site 
where the pain is felt and the site where the pain originates are the same, it is likely that 
the diagnosis appears to be correct and the diagnostic process seems to be straightfor­
ward. The use of provocation tests (palpation or percussion) and / or local anesthesia tests 
may help in establishing the source of pain. However, it is rather common in the orofacial 
area that the site of pain perception does not correspond to the source of the pain ( 0 ke­
son, 2005). This is mainly due to effects of peripheral and central sensitization, which 
may easily occur in cases where the pain source is in deep somatic tissues (Okeson, 2005). 
In persistent and chronic pain, one must be aware of secondary pain phenomena, such 
as secondary hyperalgesia and pain referral to other sites than where the pain originates. 
In addition, psychosocial effects are more prominent in these conditions. These factors 
likely limit the conditions in which this strategy can be applied. 
Figure 1 .  Diagnostic strategies in chronic orofacial pain 
1 2 3 
Assess s ite of pain Assess pain characteristics Assess effect of 
pharmacological agents 
y y y 
Identify source of pain Identify agreement of Identify pain mechanism(s) 
characteristics with known pain 
diagnosis 
y y y 
Diagnosis Diagnosis Diagnosis 
y y y 
Treatment Treatment Treatment 
In many pain conditions, the pain complaint is presented in a characteristic way. Zakrze­
wska (2001) has termed these pain characteristics "the nine symptoms of pain" (table 1). 
For example, the character of the pain, periodicity and severity may be diagnostic for 
specific pain disorders such as trigeminal neuralgia. In addition, pain may be associated 
with specific signs. For example, pain occurring on biomechanical function or associ-
The effect of an intravenous diagnostic test on nociceptive, neuropathic and 
sympathetically maintained pain 
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ated with jaw movement restriction is suggestive for a musculoskeletal pain disorder. 
A limitation to this strategy is that the presentation of the pain should not be obscured 
by non-specific manifestations or sensations, which is usually the case for chronic pain 
conditions, thus confusing and frustrating the diagnostic process. 
A third approach may be the use of pharmalogical agents aiming at specific mechanisms 
to diagnose the pain. Several pharmacological agents have been described to specifically 
affect basic pain mechanisms, i.e. nociceptive pain, neuropathic pain, and sympatheti­
cally maintained pain (Meyerson, 1997). These drugs could be of assistance in the disen­
tanglement and diagnosis of different chronic pain states, as has been suggested in previ­
ous studies (Sorensen et al., 1995; Sorensen et al., 1996 Sorensen et al., 1997). However, 
for the purpose of additional diagnostic information in orofacial pain conditions, this 
method has only partly been explored (Scrivani et al., 1999; Baad-Hansen., 2008; Tjakkes 
et al., 2009). 
Recently, a pharmacological diagnostic test has been developed, that calls on the response 
of pain patient to consecutive pharmacological agents that are administered intravenous­
ly. This test has been shown to have the ability to distinguish different responder groups 
in a chronic orofacial pain population (Tjakkes et al., 2009). Suggestions have been made 
that the test components affect distinct pain mechanisms. These suggestions are mainly 
based on theoretical considerations, and partially supported by clinical studies. The va­
lidity of the pharmacodiagnostic test has not been studied prospectively. 
To enhance the diagnostic process, an alternative strategy is of great importance. There­
fore, the aim of this study was to assess the effect of the proposed pharmacodiagnostic 
test in patients with known types of pain, i.e. nociceptive pain, neuropathic pain, and 
sympathetically maintained pain. 
Table 1 .  The nine symptoms of pain 
Character of the pain 









What sort of pain is it? 
When did it start? Did it start suddenly? 
Is there a pattern to the pain? 
How severe is the pain, how does it vary? 
Where do you feel the pain? 
Where does the pain spread? 
Does anything make the pain worse? 
Does anything make the pain better? 
Do you notice anything else when you have pain? 
Materials and methods 
Patients 
Patients that met the diagnostic criteria representing one of the three distinctive mecha­
nisms described below were approached for participation. 
N ociceptive pain patients 
Patients who have their third molars removed typically show a peak in pain one day after 
the surgery (White et al., 2003 ). In analgesic efficacy, this pain model is comparable to 
other postsurgical pain situations (Barden et al., 2004 ). Patients referred to the depart­
ment of Oral and Maxillofacial Surgery of the University Medical Center Groningen 
(UMCG) for removal of two impacted lower third molars were approached to partici­
pate in the present study. All eligible participants were informed about the nature of the 
study and the consequences for participation, i.e. time path, logistics, test procedure, and 
used agents (as described below). When they agreed to participate, an informed consent 
was read and signed. After removal of one of the lower third molars, the patients received 
a new appointment for the removal of the lower third molar on the contralateral side as 
well as an appointment for performing the pharmacodiagnostic test for the day after the 
surgical procedure. Patients were instructed not to take any pain medication on the day 
of test. 
N europathic pain patients 
Patients visiting either the department of Neurology or the Pain Management Center 
of the UMCG with neuropathic pain were approached for participation. For the neuro­
pathic pain mechanism, we included patients that were diagnosed with 1. mononeuropa­
thy (damage to a single peripheral nerve), 2. polyneuropathy (damage to more than one 
peripheral nerve), or 3. postherpetic neuralgia (chronic pain with skin changes in one or 
more roots of a cranial root subsequent to acute herpes zoster). The diagnosis was con­
firmed by an experienced neurologist. When patients agreed to participate, they signed 
an informed consent. 
Sympathetically maintained pain patients 
For the sympathetically maintained pain (SMP) group, we approached patients to par­
ticipate who were referred to the Department of Rehabilitation of the UMCG for the 
management of Complex Regional Pain Syndrome I (CRPS-I). The criteria used for di­
agnosing CRPS 1 have been described by Veldman (Veldman et al., 1993). In addition, 
patients from the Pain Management Center of the UMCG who had undergone a sym­
patheticolytic procedure by means of a successful stellate ganglion blockade or ptery­
gopalatine ganglion blockade with a pain relieving effect ( defined by a decrease in VAS 
score of at least 50%)  were invited to participate. When patients agreed to participate, 
they signed an informed consent. 
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Exclusion criteria 
Exclusion criteria for all patients were: pregnancy, age under 18 years, porphyria, and 
insufficient understanding of the Dutch language. 
This study was approved by the Medical Ethical Committee of the UMCG. 
The pharmacodiagnostic test 
To perform the pharmacodiagnostic test, patients were hospitalized for half a day at the 
UMCG. After confirmation of absence of exclusion criteria, patients were placed on a 
bed where vital signs (i.e. heart rate, blood pressure, oxygen saturation) were monitored. 
The patients were provided with a 100 mm Visual Analogue Scale (VAS) to indicate their 
pain intensity on request (Price et al., 1983 ). The endpoints of the VAS were designated 
as 'no pain' and 'worst pain imaginable'. Subsequently, the use of the VAS and the test 
procedure were thoroughly explained. 
A 20-gauge needle was inserted into a suitable vein of the arm and an infusion system 
was connected. 
The following agents were administered intravenously in fixed doses and in a specific 
order, as indicated below, with a ten-minute interval: 
Saline (0.9%) 1 0  ml 
Saline (0.9%) 1 0  ml 
Phentolamine 5 mg in 5 min 
Saline (0.9%) 1 0  ml 
Fentanyl 50 µg 
Naloxone 400 µg 
Saline (0.9%) 1 0  ml 
Lidocaine titration 200 mg in 60 min 
Before and after needle insertion and prior to drug delivery, two baseline pain ratings 
were taken in order to assess the current pain level. Furthermore, after each drug or saline 
delivery the pain intensity was assessed with the VAS at fixed time intervals. Any side 
effects occurring during this test were monitored and recorded. 
Statistical analysis 
For the three groups, the VAS score after each infusion was compared with the aver­
age of the two baseline VAS scores. This change was calculated as a percentage increase 
or decrease . Linear multilevel analysis is an extension of linear multivariate regression 
analysis, in which it is assumed that there is a hierarchical structure of at least two levels 
with different properties . For the present study, patients were repeatedly measured over 
time and these observations within a patient should not be analysed as being independ-
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ent. By defining a multilevel hierarchical structure with 2 levels (i.e . amount of pain over 
time being the highest level, and observations on patient level being the lowest level), a 
correction is made for the dependency of the observations over time. Thus, a 2-level lin­
ear multilevel analysis was executed and in this way regression coefficients were adjusted 
for dependency and their standard deviations were calculated. 
The analysis aims at retrieving a regression equation of the following form: 
Y;;= Bo;; + B 1 ; + B2;+ e; ( 1) in which Yi; is the outcome variable, B0ii is the coefficient of the intercept (in a model that allows a random slope which is comparable to a random effects model, in which i is the ith 
observation on patient j), B 1 ; and B2; are the coefficients of the slopes and e; is the residual of the jth unit. 
As we aimed at distinguishing between three groups, dummy variables were introduced, 
to "switch off and on" the slope variables; B 1 and B2 are coefficients of dummy variables. These group dummies introduced for multilevel analysis were as follows: 
Nociceptive pain group 
N europathic Pain 










Painii= Boij + B 1iGrpDmyl + B2iGrpDmy2 + e; (2) in which Painii is the VAS score of perceived pain intensity after delivery i in patient j, B0ii is the coefficient of the intercept ( constant) for the ith observation in patient j, B 1i and B2. are the coefficients of the slopes of group dummies as defined above, and ei is the residual ( error term). 
All analyses were executed in MlWin version 2.12. (Centre for Multilevel Modelling, 
University of Bristol, Bristol, UK). The level of significance was set at a<0.05. 
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Resu lts 
The nociceptive pain group consisted of 12 patients (10 females and 2 males, mean age 22.7, SD 3.7yrs), the neuropathic pain group of 10 patients (8 females and 2 males, mean 
age 43.4, SD 6.1 yrs), and the SMP group of 4 patients (all females, mean age 44.7, SD 
9.7yrs). Neither during nor after the pharmacological testing, any adverse effects oc­
curred and all patients underwent the test uneventfully. 
The relative VAS changes, i.e. the percentage change (increase or decrease) after all in­
fusions, compared to the average of the two baselines, were calculated and the results 
are shown in figure 2. When the results of the separate pain groups are judged, the fig­
ure shows that in the sympathetically maintained pain group, the VAS decrease after 
the phentolamine infusions is larger compared to the previous two infusions. The VAS 
decreases even more after the fentanyl infusion, with minimal changes after naloxone 
infusions. The nociceptive pain group shows also a major decrease of VAS after fenta­
nyl infusion. This VAS decrease is less apparent after the subsequent naloxone infusion. 
Between the three groups, it becomes clear that the effect of the fentanyl infusion is less 
pronounced in the neuropathic pain patients than in the nociceptive pain and sympa­
thetically maintained pain groups. 
Multilevel analysis yielded the following model: 
Painii= B0ii + B,iGrpDmyl + B2iGrpDmy2 - 1.49 (0.15) Agei (3) The regression coefficients listed in table 2 indicate the estimated difference of pain be­
tween the groups for the 13 observations and for the 26 participants of the study. For 
example: the difference, estimated by the model, of a patient from the nociceptive pain 
group in comparison of a patient of the SMP group is expressed by the value of B2i if the age is identical: 
Painii= [B0ii + 0 + B2/1 - 1.49 (0.15) Age) - [B0ii + 0 + 0 - 1.49 (0.15)] = B2i The statistical significance for all coefficients indicates that the course of the test differs 
between the three pain groups. Also following from the retrieved equation (3), 'age' ap­
peared to be a confounder, indicating that with increasing age, the perceived pain tends 
to decrease. 
Table 2 .  Multilevel testing for three groups 
Independent B sd p 
Nociceptive pain group 58 .8 3 .7  0 .00 
Neuropathic pain group 62.3 3.9 0.00 
Sympathetically maintained pain group 69.6 5 .2 0 .00 
Age -1 .49 0.2 0.00 
B: coefficient sd :standard deviation p: probability 
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Discussion 
This study examined the effects of administrating different pharmacological agents in 
patients with different types of pain. As we intended to cover the three most commonly 
distinguished pain mechanisms (i.e. nociceptive, neuropathic and sympathetically main­
tained pain), the pharmacodiagnostic test was conducted in patients with specific condi­
tions, mainly based on their clinical characteristics, which are thought to represent these 
pain mechanisms respectively. Based on a multilevel analysis, the course of the test ap­
peared to differ significantly between the three pain groups. 
The patients who had their third molar removed the day before the test were requested 
to refrain from pain medication intake on the day of the test, as this could affect the pain 
intensity and, therefore, the baseline VAS, which would make subsequent VAS scoring 
after drug infusion more complicated. Abstination of medication intake could of course 
not be obliged, but prior to the test, all patients indicated that they had not taken any 
analgesic medication. In the neuropathic pain and the SMP groups, the pain diagnoses 
were made regardless of the use of any medication. To facilitate the patients' willingness 
to participate and to maintain patients' comfort, we decided not to let the patient stop 
any medication, in case of medication use. 
Despite of possible medication use, all patients that entered the study and underwent 
the pharmacodiagnostic test perceived pain. Medication use could have been of influence 
on patient's responses. On the other hand, previous results have shown that medication 
use did not influence the ability of the test to differentiate between different responder 
groups (Tjakkes et al., 2009). Moreover, the three pain groups could be differentiated, 
irrespective of any medication use. 
In our study, patients from the three different pain mechanism groups received a series of 
pharmacological infusions, and VAS pain ratings were obtained. Our test was composed 
of different pharmacological agents, based on earlier findings. In these studies, nocicep­
tive pain has been identified by fentanyl (Gowing et al., 2003). The effect of the opi­
oid could be reversed by the use of fentanyls antagonist naloxone (Brunton, 2006). For 
sympathetically maintained pain, phentolamine has been shown to be effective (Arner, 
1991; Raja et al., 1991). Finally, the administration of lidocaine has shown to eliminate 
neuropathic pain (Wallace et al., 1996; Challapalli et al., 2006) In order to account for dif­
ferences in baseline VAS scores, the relative changes (compared to baseline) were calcu­
lated and illustrated in figure 2. By "eyeball judgement" of figure 2, there is a difference 
in response after the fentanyl infusion between the nociceptive pain and SMP groups on 
one hand and neuropathic pain group on the other. Between the nociceptive pain group 
and the SMP group, there tends to be an increase of pain after the naloxone infusion in 
the nociceptive pain group, whereas the change in the SMP group stays similar. The pain 
diminishing effects of the administered agents, as would be expected from the different 
pharmacological agents, on the three pain groups was not undoubtfully confirmed in our 
study. Because of the relatively small groups, no clear distinctions could be made, based 
on the separate VAS scores and relative VAS changes for each infusion between the three 
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Figure 2. Percentual change (S.E.) of VAS score (measured after infusion of the agent) compared to 
the average basel ine VAS 
20 








2 3 4 5 6 7 8 9 1 0  11 
• nociceptive pain 
e neuropathic pain 
O sympathetically maintained pain 
Measurement moment after infusion of the following agents: 
2. Saline (0.9%) 
3 .  Phentolamine 
4 .  Saline (0.9%) 
5. Fentanyl 
6. Naloxone 
7. Saline (0.9%) 1 0  ml 
8. Lidocaine 50 mg 
9. Lidocaine SO mg 
1 0. Lidocaine SO mg 
11 . Lidocaine SO mg 
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pam groups. 
We used a multilevel model for the analysis of our data. Traditional "single level" models 
fail when data are hierarchically structured, because the assumption of independence is 
violated. From a statistical point of view, the application of multilevel analysis has been 
proven to be more precise. Moreover, it has argued that these models are conceptually 
enriching (Leeden van der, 1998). Studies in the dental literature often use baseline data 
and subsequently compare measured values with baseline values. The problem with us­
ing regression or correlation between of the change in an outcome value compared to 
baseline is that of which is called "mathematical coupling", a statistical artefact (Blance 
et al., 2007). The change can be expressed as a function to the baseline and, therefore, 
the two values are coupled. In addition to mathematical coupling, the phenomenon of 
"regression to the mean" may be of concern in these situations (Tu et al., 2007). This 
occurs with any variable that fluctuates within an individual or a population (due to 
physiological variation and/or combination with measurement errors). So, preferably a 
statistical technique is used that incorporates the baseline value(s) into its analysis. The 
multilevel model to analyse change in relation to baseline without mathematical coupling 
is the model in which the baseline and follow-up values are specified on one level (level 1 ), 
clustered within individuals (level 2) (Blance et al., 2007). Multilevel analysis of previous 
data of reports on pharmacodiagnostic research may result in alternative conclusions 
concerning the effect of different pharmacological agents in patients with different pain 
mechanisms. In our study, we used the VAS values of pain perception as the first level 
and the patients as the second level. Our model showed that VAS pain scores obtained 
after pharmacodiagnostic testing from three distinct pain groups did statistically differ 
from each other, throughout the course of the test. 
In addition to the possibility of distinction between the three pain groups, age was found 
to play a significant role in the equation, indicating that age influences the primary out­
come measure (i.e. age is a confounder). So in our sample, with increasing age patients 
reported relatively lower pain intensities. There is little information about the effect of 
age on pain experience, but there are suggestions that the similarities between younger 
and older pain patients are more remarkable than the observed differences (Corran et 
al., 1997). In chronic pain patients, higher pain ratings were found in a younger cohort 
when compared to an older cohort. It was suggested that comorbidity in older patients 
may prompt referral to a pain clinic, resulting in patients with relatively lower pain rat­
ings and pain (Helme, 2001 ). As our sample consisted of a group of acute pain patients 
and chronic pain patients, it is unsure whether this explanation may also account for 
our sample. As in other strategies in the diagnostic process, pain chronicity itself seri­
ously hinders a straightforward assignment of patients into subgroups based on single 
pain mechanisms. Apart from the peripheral and central changes in the nervous system, 
the influence of psychosocial factors will be of relatively more influence and should be 
seriously taken into account (Sessle, 2000). Peripheral sites of action of the administered 
drugs may play a minor role in these patients due to central, neuroplastic changes. Also, 
neuronal changes that occur in chronic pain patients appear to affect pain behaviour 
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(Sessle, 2005). In addition, a shift in the origin of pain from somatosensory input to af­
fective, cognitive and behavioural inputs of pain may take place, which in turn influences 
the response to the administered drugs (Meyerson, 1997). Therefore, patients should 
be challenged with an intravenous pharmacological test in a relatively early stage of the 
existence of pain of unclear origin (preferably before chronicity has been allowed to be 
firmly established)in order to reveal additional information regarding mechanisms com­
pared to the effect of the test in pain patients with chronic history of extensive duration. 
In the test low and fixed doses of drugs were used to minimise adverse effects, to estab­
lish a relatively short wash-out period, to prevent carry-over effects, and to make the test 
not too time consuming. However, due to variations in pharmacokinetics and pharmaco­
dynamics in individuals, it might have been more appropriate to adapt the dosages to the 
patients' weight to improve the response effect. Another commonly used individual ap­
proach is titration of medication. In a titration setting, the dosage is increased until pain 
relief (or another outcome measure, such as 33% or 50% decrease in VAS pain score), the 
maximum dosage without sufficient pain relief, or undesired side effects are attained. The 
consequence is, however, that the washout period will increase, leading to an extension 
of duration of the test, especially when administration of several medications is desired. 
It might also have been appropriate to individualize the dosage based on the body mass 
of each patient and let that dosage be a starting point for a subsequent titration. By indi­
vidualizing the test dosages, the differential effect(s) of the administered pharmacological 
agents may become more obvious. Despite the consequence that individualising dosages 
leads to an extension of the test duration, it is certainly worthwhile to take optimizing 
measures to change the test-setup in specific patients, as the main goal is to identify, ( or 
even confirm) possible pain mechanisms in patients who suffer from their chronic pain. 
Pharmacological pain analysis has previously been used to classify pain within an in­
dividual. (Sorensen et al., 1995; Sorensen et al., 1996 Sorensen et al., 1997; Tjakkes et 
al., 2009). In these studies, patients were hospitalized during several days, receiving one 
pharmacological agent every day. These agents were titrated until the desired effect (i.e. 
pain diminishing) or undesired effects (side effects) occurred. For practical reasons, we 
have used a pharmacodiagnostic test which can be completed within half a day and which 
would cover different pain mechanisms. When a single drug mechanism is fully tested 
(using individually tailored dosages, titrating on effect), a more profound statement con­
cerning the effect of the drug can be made. If needed, a subsequent test, using an alterna­
tive drug, may be performed. 
The challenge, however, lies in obtaining useful additional diagnostic information in pa­
tients with a pain condition that cannot be readily classified with existing criteria. This 
will have a major effect on the assessment of these patients, and it will greatly improve 
the subsequent treatment modalities. Unfortunately, it is yet not possible to use the cur­
rent test in a chronic pain patient and to classify this patient into a specific pain group, 
or to determine the pain mechanisms which are likely in a patient. Also, our study did 
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not examine the effect of subsequent treatment. Therefore, further research is needed 
to confirm the usefulness of distinction into three pain mechanisms in chronic orofacial 
pain patients. 
In conclusion, the current study shows that the pharmacological test is able to differenti­
ate between specific pain mechanisms. Future research should aim at identification of 
the separate test components responsible for this distinguishing capability. The pharma­
codiagnostic test may be improved, e.g. by correlating test outcomes with the effect of 
subsequent treatment, in order to be able to judge the clinical relevance of the test out­
comes and predict treatment outcomes. This may enhance the diagnostic armentarium in 
(chronic) orofacial pain. 
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TM D pain : the effect on health related quality 
of life and the influence of pain duration 
This chapter is based on: TMD pain: the effect on Health related Quality of Life and the influence of 
pain duration. Tjakkes GH, Reinders]], TenVergert EM, Stegenga B. Published in Health and 
Quality of Life Outcomes 2010: 2; 8:46. 

Abstract 
Aims: As impact of literature concerning this subject is scarce, the objectives of this 
study were to assess whether the health related quality of life (HRQoL) is decreased in 
patients with painful temporomandibular disorders (TMD) as compared to the HRQoL 
in the general population, and to evaluate to what extent pain duration affects HRQoL. 
Methods: Data concerning physical and mental health were retrieved from patients with 
painful temporomandibular disorders. Assessment tools used were: the Mandibular 
Function Impairment Questionnaire, the Short-Form-36 (SF-36), the Hospital Anxiety 
and Depression Schedule, and the General Health Questionnaire. In order to examine 
the influence of the duration of pain on HRQoL, the total sample was divided into three 
different subgroups. Subgroup 1 consisted of patients with complaints existing less than · 
one year. Patients with complaints from 1 to 3 years were allocated to the second group. 
The 3rd subgroup included patients with complaints longer than 3 years. 
Results: The total sample consisted of 95 patients (90 females and 5 males). On most 
physical and social functioning items, groups 2 and 3 scored significantly worse than 
the general population. On the other hand, none of the groups differed from the general 
population when comparing the mental items. Duration of pain was significantly corre­
lated with SF-36 subscale physical functioning and the mandibular impairment. 
Discussion: Patients with TMD pain less than one year score better than compared to 
the population norm. With a longer duration of pain, mental health scores and role limi­
tations due to emotional problems do not appear to be seriously affected by reduced 
physical health, while social functioning appears to be considerably affected. 
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Introduction 
Temporomandibular disorders (TMD) comprise a group of disorders that affect the tem­
poromandibular joint (TMJ), the masticatory muscles, or both. TMD involve musculo­
skeletal pain, disturbances in the mandibular movement patterns, and / or impairment in 
functional movement (Stegenga, 1991). Pain is the main characteristic of most TMD and 
also the main reason for patients to seek treatment (Dworkin, 2006 ). Many TMD should 
be considered chronic pain conditions, since they show lot of similarities (Dworkin and 
Massoth, 1994). Psychological factors have been implicated in the initiation as well in the 
perpetuation of several TMD (Yap et al., 2002). Stress, somatic distress, and depression 
may be potential etiological risk factors for TMD-related pain (Zakrzewska and Harri­
son, 2002). When the duration of pain increases, psychological factors may become more 
obvious and prominent. Even after a decrease of the somatosensory input, suffering and 
pain behaviour may continue and even increase (Okeson, 2005). 
It is generally accepted that quality of life is negatively affected by chronic pain (Kem­
pen et al., 1997; Schlenk et al., 1998). The impact of TMD (and other types of orofacial 
pain) on health related quality of life (HRQoL), however, has scarcely been described. 
Recently, Naito et al. conducted a systematic review on oral health status and health­
related quality of life (Maito et al. 2006). They found only one study concerning TMD. 
In this study, Reisine and Weber observed a sample of 30 patients with temporomandibu­
lar disorders, during 6 months (Reisine and Weber, 1989). Different aspects of HRQoL 
were investigated e.g. anxiety, perceptions and social functioning. It was found that while 
the pain decreased over time, oral and functional aspects did not improve significantly 
within the same period of time. This result may be due to a slower response of other pa­
rameters to treatment in contrast to a relatively rapid response of pain. Furthermore, the 
authors found relatively poor ratings of well-being and high levels of anxiety, suggesting 
that TMD patients are characterized by relatively negative psychological states, and that 
when pain persist (even when diminished) functional aspects do not improve. 
Murray and collegues described the HRQoL, as measured with the Oral Health Impact 
Profile (OHIP), of patients referred to a craniofacial pain unit because of TMD and facial 
pain (Murray et al., 1996) With regard to pain-related disability and HRQoL, 29.7 % of 
the sample reported a frequently disturbed sleep as a consequence of their oral condi­
tions, and 36.4 % reported feelings of depression. Different researchers have found a 
larger impairment of the oral HRQoL in TMD patients compared with healthy popula­
tion, using the OHIP (Segu et al., 2005; John et al., 2006). 
LeResche and collegues studied the facial expression as well as states of anxiety, depres­
sion, somatization and daily stress in a group of TMD pain patients, subgrouped into 
a chronic and non-chronic category (LeResche et al., 1992). With regard to these four 
aspects of HRQoL, no differences were found between a group of patients that perceived 
pain for the first time within the last two months (non chronic group) and a group that 
suffered from pain for over 6 months ( chronic group). 
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It is not clear whether and, if so, how (chronic) pain related to TMD influences HRQoL, 
and whether pain duration is of influence. It may be hypothesized that when pain has 
just begun, this will mainly affect physical factors such as physical functioning. When 
the pain lasts for a longer period, and treatment so far has failed to relieve the pain, it 
may start to have more impact on the emotional behaviour, social factors and HRQoL. 
However, whether this is the case is yet not clear. Information concerning the influence 
of pain and its persistence on HRQoL may guide treatment in these patients. Therefore, 
the aims of this study were to assess whether the HRQoL is decreased in orofacial pain 
patients as compared to the general population, and to study the effect of duration of 
pain on HRQoL. 
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Methods and Materials 
Sample 
Patients were recruited from the department of Oral and Maxillofacial Surgery of the 
University Medical Center Groningen (UMCG). The group consisted of 95 patients 
consecutively consulting the TMD/Orofacial Pain section for their orofacial pain prob­
lems. The inclusion criteria were age over 16 years, no language barrier, and the pres­
ence of a painful temporomandibular disorder as classified according to the RDC/TMD 
(Dworkin and LeResche, 1992; Lobbezoo et al., 2005). From the axis II information, the 
duration and impact of the pain were assessed. The influence of the duration of pain on 
HRQoL was examined by two means. Firstly, the total sample was divided into three 
different subgroups. Subgroup 1 consisted of patients with complaints existing less than 
one year. Patients with complaints from 1 to 3 years were allocated to the second group. 
The third subgroup consisted of patients with complaints longer than 3 years. Secondly, 
the influence of the duration of pain was studied using results of the total sample in re­
gression analysis. During their first visit to the clinic, patients were informed about the 
study and the content of the questionnaires. When patients were willing to participate, 
they were requested to fill in an informed consent. 
Quality of life has been described by the World Health Organisation as " . . .  an indi­
vidual's perception of their position in life in the context of the culture and value system 
of which they live with the relation to their goals, expectations, standards and concerns." 
This concept incorporates different aspects of individuals, including physical health, psy­
chological state, level of independence, social relationships, personal beliefs and their 
relationship to salient features of the environment (WHOQoL, 1995). 
Assessment and Instruments 
During the second visit to the clinic, patients were instructed how to complete the ques­
tionnaires. Subsequently, patients were left alone to complete the questionnaires. When 
necessary, unclear test items could be clarified by the interviewer. Only Dutch versions 
of the questionnaires were used. 
HRQoL was measured by the following instruments. 
SF-36: The Medical Outcome Short Form Health Survey, a 36 item health survey, was 
used to assess the patients' HRQoL (Hays et al. 1993). It includes eight health concepts: 
physical functioning (PF, measuring the physical activities), role limitations due to physi­
cal health problems (RP, measuring the effect of the physical health on work and daily 
activities), bodily pain (BP), general health (GH) perceptions, vitality (VT, measuring 
energy/fatigue), social functioning (SF), role limitations due to personal or emotional 
problems (RE, measuring the effect of the emotions on work and daily activities) and 
general mental health (MH including anxiety and depression). The scores on every sub­
scale range from 0-100, with higher scores indicating better health states. Reference val­
ues were used to compare the results of the group in question. The reference values were 
taken from a Dutch study, which consisted of a random Dutch sample of 1742 persons, 
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which is used as the reference group (Aaronson et al., 1998). In this study the mean values 
for each subscale were for PF 83.0 (sd 22.8), RP 76.4 (sd 36.3), BP 74.9 (sd 23.4), GH 70.7 
(sd 20.7) VT 68.8 (sd 19.3), SF 84.0 (sd 22.4), RE 82.3 (sd 32.9), MH 76.8 (sd 17.4). 
MFIQ: The Mandibular Function Impairment Questionnaire was used to obtain infor­
mation about the function impairment of the jaw. It was developed to provide for a 
tool, additional to the clinical assessment, for assessment of function impairment in the 
patients own value system (Stegenga et al., 1993). It comprises 17 items, concerning man­
dibular functions e.g. speaking and eating different types of food. A functional impair­
ment rating score (FIRS) can be retrieved. This is a score ranging from O (no function 
impairment) up to 5 (indicating severe function impairment). 
HADS: To assess depression and anxiety in a hospital setting, the HADS was used. To 
screen for anxiety (HADS-A) the odd items were used. For the screening of depression 
(HADS-D), the even items of questionnaire were used. On each subscale, scores up to 
7 indicate no signs of anxiety or depression, scores between 8 and 10 suggest probable 
anxiety or depression, and scores over 10 indicate the presence of anxiety or depression, 
respectively (Zigmond and Snaith, 1983 ). 
GHQ-28: The general health questionnaire was used to assess different types of psychi­
atric distress. It is a 28 item list which can be divided into four different subscales: so­
matic symptoms (GHQA), anxiety and insomnia (GHQB), social dysfunction (GHQC) 
and severe depression (GHQD) (Goldberg and Hillier, 1979). The reference values were 
for GHQA 6.2, GHQB 5.8, GHQC 7.0, GHQD 1.6 and were retrieved from a general 
Dutch population of 485 persons (Koeter and Ormel, 1991). 
Sample size calculation 
To estimate the a priori sample size, an effect size of 0.4 was chosen. By convention this 
effect size is considered as a moderate effect size. Sample was calculated on an ANOVA 
with the parameters a, B, number of groups and effect size. a. was set at 5%, B at 10%,  
number of  groups 3 ,  resulting in a critical F of  3.10931. The total calculated sample was 
84. To account for possible dropouts, sample size was about 10% increased to 95. 
Statistical analysis Descriptive statistics were performed to summarize sample characteristics. Data were 
tested for normality using the Kolmogorov-Smirnov test. By means of one sample t­
tests, the HRQoL scores of the patients were compared to those of a general population. 
To test mean differences in HRQoL among subgroups, one-way ANOVA was carried 
out, followed by Scheffe's post hoc multiple comparison test in case of a significant re­
sult. In order to study the association between the duration of pain and the scores on the 
different SF-36 subscales, HADS scores, GHQ-28 scores, and MFIQ score, respectively, 
Pearson correlation coefficients were calculated. Outlier analysis with scatter plots was 
performed to look for possible difference in scores between female and male participants. 
Data from the total sample was analysed in a regression analysis. Data were analyzed 
using SPSS 14 (SPSS Inc, USA). The level of significance was set at 0.05. This study was 




In total 95 patients (90 females and 5 males) provided their consent to participate in the 
study. Their average age was 40.3 yrs (sd 13.1, ranging from 17-69). According to the 
RDC/TMD, patients were diagnosed with a group I diagnosis (myofascial pain), a group 
II diagnosis (disc displacement) a group III (arthralgia, osteoarthritis and osteoarthrosis). 
A group I diagnosis was established in 31.9%; a group II diagnosis in 4.4% and a group 
III in 35.2%. A combined diagnosis was made in 28.7% of all cases (in 7.8% group I and 
II, in 17.6% group I and III, and in 3.3% group II and III were combined). Furthermore, 
the participants of the 3 subgroups based on pain duration were calculated: subgroup 1 
(pain present for less than one year) consisted of 15 patients (14 females; 1 male, mean 
age 37.7 yrs, sd 14.4, range 17-69), subgroup 2 (1-3 years pain duration) consisted of 16 
patients (13 females, 3 males; mean age 37.5 yrs, sd 14.1, range 20-68), and subgroup 3 
(more than 3 years of pain) consisted of 64 patients ( 63 females, 1 male; mean age 41 .6 yrs, 
sd 12.5, range 17-67). The distribution of the diagnoses, medication use and coinciding 
chronic pain diseases among the three groups is listed in table 1. 
Effects of pain duration: Three groups 
Results compared with reference values 
Table 2 shows the mean SF-36 and GHQ scores for the three subgroups. The first ("rela­
tively acute") subgroup scored better on the subscale physical functioning and worse on 
subscales general health and vitality than the general population, but on the other sub­
scales this subgroup and the general population revealed comparable scores. 
Compared with the general population, the second subgroup scored worse on four sub­
scales (bodily pain, vitality, general health and social functioning) and the third subgroup 
scored worse on six SF-36 subscales (bodily pain, vitality, general health, social function­
ing, physical functioning and role emotional). 
In the first and second group, scores on the GHQ scales did not significantly differ from 
scores in the general population. The third group showed more impairment in somatic 
symptoms and showed higher social dysfunction, with worse scores on GHQA and the 
GHQC, compared to those obtained from the general population. 
Comparisons between groups 
No differences were found in age between the three groups. Statistically significant dif­
ferences were found between groups 1 and 3 with regard to the SF-36 subscore on the 
scales physical functioning and bodily pain (i.e. scores were better in group 1 ), but not 
between groups 2 and 3. Other SF-36 scores did not differ significantly between the three 
groups. 
The third group showed more somatic problems as well as a higher level of social dys­
function compared to the first group, as GHQA and GHQC scales revealed significant 
differences between these groups. 
The patients' impairment in mandibular function, as assessed with the MFIQ and ex-
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pressed in the FIRS, was 2.4 (sd 1.1) for the first group, 2.6 (sd 2.0) for the second group, 
and 3.3 (sd 1.6) for the third group, indicating moderate impairment in these three sub­
groups (table 2). No significant differences between the three groups were found in the 
FIRS. 
Both HADS-A and HADS-D scores were worse in groups 2 and 3 as compared to group 
1 (table 3). In addition, the HADS-D score in group 2 was worse than in group 3. 
Effects of pain duration: total sample 
The social, psychological and part of the physical measures did not show significant cor­
relation with pain duration. Of all calculated correlations, the SF-36 subscale bodily pain 
and the FIRS were significantly correlated with the duration of pain. 
Outlier analysis revealed no differences on the subscales in any of the assessed subscales 
between female and male patients. 
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Table 1 .  Distribution of age. RDC diagnoses medication usage and coinciding chronic pain disor­






Group I I  
Group I l l  
Group I + group 1 1  
Group I + group I l l  






Tricyclic antidepressant + paracetamol 
Tricyclic antidepressant + NSAID 
NSAID + opioid 




Group 1 : Myofascial pain 
Group 2: Disc displacement 
Group 3: Arthralgia/ osteoarthritis/ osteoarthrosis 
NSAID :  Non-steroidal anti-inflammatory drug 
2 






















74.9 (23 .4) 
70. 7  (20 .7) 
68.8 (1 9.3) 
84.0 (22 .4) 









92.1 (8 .1 )* 3 
54 .2 (38.1 ) 
66.1 (20.4) 3 
53.0 (23.4)* 
52 .9 (1 4.9)* 
74 .0 (22 .9) 
66 .7 (31 .8) 
66.4 (1 2 .5) 
6 .7  (4.1 ) 
2 .8  (2.1 ) 2 
6 .6 (1 .8) 3 




74.2 (33 .1 )  
71 .2  (3 .6) 3 
53 .2 (27.5) * 
55 .8 (1 8. 7) * 
49.3 (21 .6) * 
66.0 (29 .2)* 
81 .0 (55 .0) 
60.6 (17.9) 3 
6.3 (4 .1 ) 
7.5 (3.6) 1 
8.2 (3 .3) 




72.3 (25. 7)* 1 
41 .2 (39.7) *2 
48.5 (1 9. 7) *1 
54.4 (20.6) * 
55.2 (1 9.4) * 
66. 7 (23 .4) * 
80.9 (34.1 ) 
73.2 (1 3 .0) 2 
8.2 (4 .0) * 
5.9 (4 .4) 
8.3 (2.3) *1 
1 .9 (3 .0) 
Values in mean (standard deviation, * p<0 .05 from reference values, in superscript the the group 
to which the value is statistically different; reference values from a Aaronson et al.1 998, b Koeter 
and Ormel, 1 991 . 
(PF, physical functioning; RP, Role l imitations physical ;  BP, bodily pain; GH, general health ; VT, 
vitality; SF, social functioning; RE, role l imitations emotional ;  M H, mental health ; SD, standard 
deviation; GHQA, somatic symptoms; GHQB, anxiety and insomnia ; GHQC, social dysfunction; 
GHQD, severe depression; P, P-value) 
Group 1 : compla ints of one year or shorter 
Group 2: complaints within 1 and 3 years 
Group 3 :  complaints longer than 3 years 
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Table 3. FIRS, HADSA and HADSD scores (standard deviation) for three groups 
Group 1 Group 2 
score 
FIRS (sd) 2.4 (1 .1 ) 2 .6 (2.0) 
HADS A (sd) 3.3 (1 .8) 2•3 6.4 (4. 1 ) 1 
HADS D (sd) 1 . 6 (1 . 1 ) 2•3 6.2 (4. 2) 1 ·3 
Group 1 : complaints of one year or shorter 
Group 2: complaints within 1 and 3 years 
Group 3: complaints longer than 3 years 
Group 3 
3.3 (1 .6) 
5.0 (3.6) 1 
3.5 (3.1 ) 1 •2 
(FI RS; functional impairment rating score, HADSA; anxiety, HADSD; depression. In superscript the 









pain  behavior  
The effect of duration of symptoms on psychosocial factors. From Okeson (Okeson, 2005). 
Used with permission. 




In this study we examined whether the duration of pain in TMD patients seeking treat­
ment affects the HRQoL and psychological well-being. When managing these patients, 
psychological assessment may lead the clinician to multidimensional, biobehavioral ther­
apy modalities rather than to somatically based therapies (Dworkin, 2006 ). Also, TMD 
patients classified into different cognitive-behavioural profiles seem to respond differ­
ently when the same treatment is offered (Dahlstrom et al., 1997). Thus, not only the 
physical but also the psychological status may influence the treatment outcome. 
The duration of pain is thought to have a significant impact on a patient's psychological 
status (figure 1) (Okeson, 2005). To provide more insight into the effect of duration of 
pain complaints, we compared patients with relatively acute pain (less than 1 year) and 
patients with chronic pain (1-3 years and > 3 years, respectively). A striking finding was 
that in all three subgroups the SF-36 scores of the subscales role emotional and mental 
health did not differ significantly from the reference values. It may be that patients with 
a longer experience of complaints tend to get used to their pain and symptoms and in­
corporate them as a part of their life, thereby leaving their mental health less affected. 
The first group did score significantly higher ("better") on the subscale physical func­
tioning, compared to the population norm. This finding could be explained by possible 
underestimation of the physical situation, when patients visit a hospital and are allocated 
to a study group that answers questions about health. Patients with pain or function 
problems that have arisen within the last year, may tend to focus on these problems in 
an opposite manner than patients who have a longer experience with these problems. In 
addition, the scale bodily pain was not significantly different from the reference value. 
Because of the relatively short existence of pain, patients may underestimate or under­
rate the consequences of their disorders on the measured scales. They may be convinced 
that (pain) symptoms will be transient and, therefore, patients will not allow them to 
affect the physical items. Patients may also feel the need to convince the doctor that the 
symptoms are purely physical, and want to display that statement in the answers of the 
subscales. 
By contrast, on SF-36 physical health items bodily pain, general health and vitality the 
second and third group scored significantly worse than reference values. In addition, 
in the third group the items physical functioning and role physical were also worse than 
reference values. This physical impairment was confirmed by the FIRS scores, indicat­
ing moderate function impairment. So the mandibular function was lowered in all three 
groups. The GHQA score, which represents the somatic general health, is significantly 
lower ("worse") in the third group, which is in accordance with the scores on the SF-36. 
With significantly lower scores on the physical scales of the SF-36, the second and third 
subgroup did not score significantly lower on the mental scales. 
Between the different pain duration groups, statistically significant differences were 
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found only on a few scales. Comparing "better" scores from the first group with "worse" 
scores from the third group, leads in the physical functioning subscale to a significant dif­
ference between those scores. Although the HADS scores are interpreted using cut-off 
points, it is striking that the depression scale (HADS-D) in group 2 is not only higher 
compared to group 1, but also compared to group 3. Patients who experience complaints 
for a short time may not be seriously affected, but when pain persists, psychological 
distress will be more pronounced. Later, when patients are used to the pain or when they 
are sufficiently reassured about their health status, the psychological distress will return 
to lower values again. This is in accordance with the score on the mental health subscale 
of the SF-36, which is better in the third group compared to the second group. 
According to our findings, it may seem that patients with a shorter duration of pain seem 
to underrate their physical impairment or at least do not consider it to be relevantly im­
paired, as the scores are "better" compared with a healthy reference group. Patients with 
longer lasting pain at least longer than one year, have more pronounced physical prob­
lems. The role limitations due to emotional problems or the mental health seem to be 
hardly affected, however. It has been suggested that psychological functioning is merely 
related to patients' beliefs and coping strategies rather than to the physical impairment 
(Turner et al., 2001). On the other hand, the social functioning scale in the SF-36 as well 
as the GHQC score suggest that social functioning is affected in the third group. This 
may be explained by role limitations due to physical limitations, which in turn may be 
the result of the actual disorder. 
In addition to the analysis with three subgroups, we calculated Pearson correlation coef­
ficients with data from all patients. This revealed a significant correlation between the 
whole range duration of pain with the subscale physical functioning and the mandibular 
impairment (FIRS). So with a longer duration of pain, the somatic well-being is consid­
ered worse. It remains unclear whether the physical discomfort has worsened during its 
existence or whether the discomfort is only rated worse due to its longer existence. Other 
subscales and other scores did not show significant correlation with duration of pain, 
which may be explained by a large range of duration of pain in contrast to the smaller 
scale range of the scores on other subscales and the other questionnaires. 
One factor that may be of influence on the results is the age. In our sample, no difference 
was found between the three groups. Besides TMD pain, other pain condition could 
play a role in HRQoL. Of the studied sample totally five had an accompanying chronic 
condition. In the second group, two suffered also from rheumatoid arthritis. In the third 
group, one patient suffered from rheumatoid arthritis, one from hernia and one from low 
back pain. These conditions could have influenced the questionnaire outcomes, although 
the number of patients is a slight minority compared to the total sample size, therefore 
we argued this to be of negligible influence. 
A limitation of this study could be the large female predominance, compared to the 
general population, which may hamper the generalizability of the results. However, a 
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predominance of female gender in TMD is also found in epidemiological research (LeRe­
sche, 1997). In addition, more female than male patients seek treatment for their pain 
problems, leading to an increasing female predominance in specialist centers, with a 
female:male ratio ranging from 2:1 to 9:1 (Bush et al., 1993). In addition, outlier analysis 
( to explore possible differences in measurements in our sample between male and female 
patients) revealed no outliers in the assessed subscales. We thus consider sex difference in 
our sample to be of minor influence and we therefore decided to include both male and 
female in the total analysis. 
In patients with chronic pain conditions, such as most TMD pains, it has been dem­
onstrated that psychological factors are better predictors of treatment outcome on the 
long-term than physical findings are (Dworkin, 1994, Turk and Okifuji, 2002). When 
TMD patients with pain less than one year are compared to a reference population, it 
was found that these patients scored better on physical functioning. However, we found 
that patients with longer lasting problems have more pronounced physical problems and 
limitations and that these limitations have impact on social functioning in this group. 
The mental health and role limitations due to emotional problems do not seem to be 
seriously affected by reduced physical activities. Especially in cases of longer duration of 
pain, where initial treatment has failed to relieve the pain, the social functioning may be 
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The effect of orofacial pain on quality of life 
as measured by different standardized 
measurement instruments compared with 
individual measurements 
This chapter is based on: The effect of orofacial pain on Quality of Life as measured by different 
standardized measurement instruments compared with individual measurements. Tjakkes GH, 
Reinders ]], Elisabeth M. Ten Vergert E.\f, Huddleston Slater ]JR, Stegenga B. Submitted. 

Abstract 
Aims: The purpose of this study was to explore whether a short, individualized approach 
reveals different information as compared to the use of standardized measurements of 
mental health and health related quality of life (HRQoL) in orofacial pain patients. 
Materials and Methods: Different standardized measurement instruments, assessing 
concepts which are likely related to HRQoL, were used. For the individualized ap­
proach, patients were asked to indicate and rate a domain that most influenced their 
health related quality of life and to rate their overall HRQoL with a mark. The results of 
both methods were combined, by calculating correlation coefficients. 
Results: When patients were asked to depict a domain that influences their HRQoL, the 
domains health and family were indicated most frequently. When comparing the results 
from the individualised and the standardized instruments, only the ratings from the do­
main health were significantly correlated with the Short Form-36 subscale mental health. 
These results suggest that a standardized assessment reveals different information than 
individualized assessment. 
Conclusion: In assessing the mental health and HRQoL in chronic orofacial pain, a 
standardized assessment is preferably combined with an individualized assessment, 
which may lead to a more complete appraisal of the HRQoL of pain patients. 
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Introduction 
Orofacial pain is a common complaint for patients to visit the dentist. Mostly, these 
cases are transient in nature, and a diagnosis will be relatively easy to establish with sub­
sequent offered treatment. However, in persisting orofacial pain, neuroplastic changes 
may occur and also, psychosocial factors become more prominent (Okeson, 2005) . To 
assess the influence of these psychological distress and social effects, specific, standard­
ized psychological measures can be used. Examples of measures used are the Hospital 
Anxiety Depression Scale (HADS) and the General Health Questionnaire (GHQ). In 
addition, gaining popularity in health assessment, quality of life (QoL) is an increasingly 
used measure of overall well-being. QoL has been described by the World Health Or­
ganisation as " . . .  an individual's perception of their position in life in the context of the 
culture and value system of which they live with the relation to their goals, expectations, 
standards, and concerns." This definition incorporates different aspects of individuals, 
including physical health, psychological state, level of independence, social relationships, 
personal beliefs and their relationship to salient features of the environment. An often 
used, standardized QoL instrument is the Short Form-36 (SF-36). 
In the assessment of health related quality of life (HRQoL), a distinction between two 
different approaches can be made, namely the "need approach" and the "want approach", 
differentiating between what someone needs and what someone wishes (Hayry, 1991). 
In the need approach it is assumed that HRQoL is determined by certain needs, such 
as health and physical performance. These needs are often considered to be conclusive. 
Hence, in this approach, HRQoL is measured by means of standardized questionnaires 
that include measurement instruments to assess these needs. On the other hand, the want 
approach allows the view of the individual, using values or factors that determine the per­
son's HRQoL (Hayry, 1991). In the past, instruments aiming at an individual approach 
of HRQoL have been developed. Qambon and Johnson, 1997; Schwartz and Sprangers, 
1999) These methods were based on the assumption that the individual is the best source 
for judging quality of life aspects which may be different for each individual (Browne et 
al., 1997). So this approach uses an individual approach without predefined factors. 
In general, patients with (chronic) painful conditions not only perceive the pain but also 
experience suffering. Thus, assessing the patient's perception of how the pain affects life 
might provide information of the extent of suffering, as the quality of life in chronic pain 
patients may be related to different factors or domains that are not exclusively related 
to the pain. It is assumed that oral health and quality of life are inextricably connected 
(Gift and Redford, 1992). Nevertheless, the exact connection between health and QoL 
is unclear. Although one might expect that when ( oral) health is negatively affected, the 
QoL will subsequently decrease as well. This consequence is not self-evident. People 
with chronic disabling disorders may perceive their QoL better than healthy controls 
(Allen, 2003 ). This may be due to the phenomenon that a subject's attitude towards the 
perceived QoL may change overtime, making the QoL a dynamic construct (Allison et 
al., 1997). 
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In the assessment of chronic orofacial pain patients, it is generally accepted that a multi­
axial approach is a prerequisite to appropriately manage these patients. Given the variety 
in methods for measuring psychological distress and HRQoL, it is clear that these con­
cepts are hard to grasp with one method. It is for instance not clear whether they should 
be assessed individually or standardized. In standardized measurements appropriate do­
mains for the individual patient may lack and, in addition, in individual measurements, 
"need" items may be overlooked. 
The purpose of this study was to explore whether a short, individualized approach in 
quality of life assessment in orofacial pain patients reveals corresponding or other infor­
mation when compared to the information obtained from standardized measurements. 
The central focus of this study is to investigate the convergent and divergent validity of 
the individualized measurements of mental health and HRQoL. 
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Methods and Materials 
Patient selection 
Patients from the section for Temporomandibular Disorders / Orofacial Pain from the 
department of Oral and Maxillofacial Surgery of the University Medical Center Gron­
ingen (UMCG), older than 16 years and without language barrier were asked to partici­
pate in a study concerning their quality of life. Patients willing to participate gave their 
informed consent and were classified according to the research diagnostic criteria for 
temporomandibular disorders (RDC/TMD; Dworkin and LeResche, 1992). 
Assessment and Instruments 
Standardized approach Generic measure: The Short Form-36 (SF-36), is a 36-item HRQoL questionnaire. (Hays 
et al., 1993, Aaronson et al., 1998) It includes eight health-related concepts: physical 
function (PF, measuring the physical activities), bodily pain (BP), role limitations due to 
physical health problems (RP, measuring the effect of the physical health on work and 
daily activities), role limitations due to personal or emotional problems (RE, measuring 
the effect of the emotions on work and daily activities), general mental health (MH, in­
cluding anxiety and depression), social functioning (SF), vitality (VT, measuring energy/ 
fatigue) and general health (GH) perceptions. The scores on every subscale range from 
0-100, with higher scores indicating better health states. 
Specific measures: The Mandibular Function Impairment Questionnaire (MFIQ) was 
used to obtain information about the function impairment of the jaw. It was developed 
to provide for a tool additional to the clinical assessment, for assessment of mandibular 
function impairment in the patient's own value system (Stegenga et al., 1993) This is be­
lieved to be of value of the quality of functioning in this group of patients. It comprises 
17 items, concerning mandibular function e.g. speaking and eating different types of 
food. A functional impairment rating score (FIRS) can be retrieved. This is a score rang­
ing from O (no function impairment) up to 4 (indicating severe function impairment). 
To assess depression and anxiety in a hospital setting, the Hospital Anxiety Depres­
sion Scale (HADS) was used (Zigmond and Snaith, 1983). On each of the two subscales 
(HADS-A representing anxiety, HADS-D representing depression), scores up to 7 indi­
cate no signs of anxiety or depression, scores between 8 and 10 suggest probable anxiety 
or depression and scores of greater than 10 indicate the presence of either anxiety or 
depression. 
The General Health Questionnaire was used to assess different types of psychiatric dis­
tress. This 28-item questionnaire yields scores on four domains, i.e. somatic symptoms 
(GHQA), anxiety and insomnia (GHQB), social dysfunction (GHQC) and severe de­
pression (GHQD), Scores per subscale range from O to 21, with higher scores indicating 
psychiatric distress. (Goldberg & Hillier, 1979; Koeter and Ormel, 1991). 
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Individual approach (IA-VAS and HRQoL mark) 
All patients were requested to state a domain of their life which they considered have 
the largest influence their health related quality of life the most, either in a positive or a 
negative way. The current value of this domain on the health related quality of life was 
rated on a Visual Analogue Scale (VAS), ranging from O (worst possible) to 100 (best 
possible). This is called the IA-VAS (individual approach visual analogue scale). Patients 
were also requested to rate their actual overall health related quality of life with a mark 
ranging from O to 10 (0 representing the worst and 10 the best quality of life imaginable), 
to which we will refer to as the HRQoL mark. 
Statistical analysis 
Descriptive statistics was used to summarize sample characteristics. Pearson's correla­
tions were calculated between the (sub)scales of the SF-36, the MFIQ, the HADS, the 
GHQ, the IA-VAS and the HRQoL mark. Correlations were judged as low (r<0.20), 
moderate (0.20 < r < 0.50) or high (r>0.50) in accordance with Cohen's recommendations 
(Cohen, 1977). The level of significance was set at p<0.05. This study was approved by 
the Medical Ethical Committee of the UMCG. 
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Results 
Patients' demographics and scores 
In total, 106 patients were approached to participate in the present study. Of these 106, 
17 decided to withdraw resulting in 89 patients (84% response), all of Dutch origin, who 
were willing to participate (84 females and 5 males; mean age 41.0 years (sd 13.2 years). 
The median duration of pain in these patients was 6.5 yrs (range 1-35 years). According 
to the RDC/TMD, a group I (myofascial pain) diagnosis was established in 32.6% of 
all patients. A group II diagnosis (disc displacement) was made in 3.4%. A group III 
(arthralgia, osteoarthritis and osteoarthrosis) diagnosis was made in 36.0%. A combined 
group I and II diagnosis was made in 4.5%, combined group I and III in 16.9% and 
combined II and III diagnosis in 3.4%. 
Standardized approach 
The outcomes of the SF-36, FIRS, HADS and GHQ are listed in table 1. When applica­
ble, the reference values are also listed. 
Individual approach 
The domains called at the answer of the open ended question were of major influence 
on their HRQoL could be categorised in the following seven domains: 1 health, 2 fam­
ily/interpersonal relationships, 3 job/education, 4 social contacts other than family or 
spouse, 5 religion, 6 hobby/sport, and 7 other. The domain mentioned most frequently 
was family/relation (64.0 %). The domain health was mentioned in 19.1 % as being 
the most important. Domains mentioned less frequently were job/ education as well as 
hobby/sport (2.2%) and religion (1.1 %). Domains allocated to the domain other were 
mentioned by 3.4% of the patients. Items mentioned allocated to this domain were in­
dependence and love. The average IA-VAS was 93.9 (sd 13.8) and the average HRQoL 
mark 71.3 (sd 13.3). 
Correlation with the individual domains 
In order to assess the relationship between domains measured in the standardized fashion 
and the domains called the open ended question, correlations were calculated between 
scores on the (sub)scales of the SF-36, MFIQ, HADS and GHQ and the ratings of the 
most frequently called domains health and family/relation. None of the SF-36, MFIQ, 
GHQ and HADS (sub)scales correlations were significantly correlated with the IA-VAS 
of domains health and family/relation. Table 2 shows that all correlations between the 
overall HRQoL (HRQoL mark) and the standardized measures (SF-36, MFIQ, GHQ 
and HADS) were statistically significant. The correlations of the HRQoL mark with the 
SF-36 ranged from .290 to .460, indicating a moderate (positive) relationship. The cor­
relations of the HRQoL mark with the FIRS, GHQ and HADS ranged from -.245 to 
-.516, indicating a moderate to high (negative) relationship. 
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Table 1 .  SF-36, MFIQ, HADS and GHQ scores 
Scale Reference Mean (SD) 
(SD) 
SF-36 PF 83.0 (22.8) 74.3 (26.6) 
SF-36 RP 76.4 (36.3) 49.3 (40.9) 
SF-36 BP 74.9 (23.4) 52.0 (22.6) 
SF-36 GH 70.7 (20.7) 55.9 (20.0) 
SF-36 VT 68.8 (1 9.3) 54.5 (1 9 .6) 
SF-36 SF 84.0 (22.4) 68.3 (24.6) 
SF-36 RE 82.3 (32.9) 82.0 (37.5) 
SF-36 MH 76.8 (17.4) 71 .0 (1 6.6) 
Used abbreviations (for questionnaire properties see text) 
SD:  standard deviation 
SF-36 :  The Short Form Health Survey, 
PF: physical functioning; 
RP: role limitations physica l ;  
BP :  bodily pain;  
GH: general health ; 
VT: vitality; 
SF: social functioning; 
RE: role limitations emotional ;  







GHQB 5.9 (4.2) 
GHQC 
GHQD 1 .8 (3.0) 1 .6 
FIRS,: function impairment ration scale; 
n/a: not available 
HADS-A: Hospital Anxiety and Depression Score Anxiety; 
HADS-D: Hospital Anxiety and Depression Score Depression. 
GHQ: General health Questionnaire 
GHQA: somatic symptoms; 
GHQB: anxiety and insomnia ; 
GHQC: social dysfunction ; 
GHQD: severe depression ; 
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Discussion 
In this study we explored whether the individualized approach reveals corresponding or 
other information compared to the information obtained from standardized measure­
ments of psychosocial functioning and HRQ0L in orofacial pain patients. These patients 
may, apart from or due to pain and physical (mandibular) impairment, suffer from psy­
chological and psychosocial problems that may influence their HRQoL. As HRQoL is a 
multidimensional construct, we decided not to include purely QoL assessment tool (SF-
36) but also questionnaires which cover dimensions of QoL. So physical and psycho­
logical dimensions, including anxiety and depression were assessed separately. In order 
to get a complete picture, the results obtained from the individualized and standardized 
approaches were compared. 
Our results showed that when patients were asked to mention domains that influence 
their HRQoL, the domain family/relation was mentioned most frequently. However, 
this domain was not explicitly taken into consideration at the standardized approach. 
Against our expectations, the domain health was only mentioned by 19.1 % of the pa­
tients as the most important domain. In the standardized approach, this domain, how­
ever, is often included by most of the instruments. As could be expected, in patients who 
mentioned health as the most important domain, the VAS score (IA-VAS) given to this 
domain was found to be significantly correlated with the SF-36 subscale mental health. 
On the other hand, the domain health was not significantly correlated with scores on the 
FIRS, the SF-36 subscales general health, pain, vitality or the GHQA (somatic) subscale. 
Similarly, when patients depict social contacts as an important domain in their HRQoL, 
one would expect that this would be reflected in the scores on the social dimensions of 
the standardized instruments. This discrepancy between the outcomes of the individu­
ally judged most important domains (in our study health and social contacts) and the 
subsequent judgement of similar domains on standardized questionnaires imply that dif­
ferent approaches serve different purposes and do actually measure different things. An 
explanation for this finding may be that, according to the patient, not all items used in the 
standardized questionnaires appeared to be related to the corresponding domain being 
mentioned as most important. A concern in this part may be the categorization of the 
named domains into seven predefined domains, as it may be susceptible to subjectivity. 
However, the domains mentioned were in large agreement with the mostly predefined 
domains, and there was a high agreement in selection of words. We therefore argue that 
this subjectivity can be ignored in the interpretation of the results. 
Furthermore, our results showed that the HRQoL mark was significantly correlated 
with the outcomes of the standardized questionnaires (SF-36, MFIQ, HADS and GHQ). 
These correlations may support the idea that in a screening or clinical setting, the overall 
rating of the patient's HRQoL mark provides a representative impression of the patient's 
HRQoL. Correlations of the HRQoL mark with the SF-36 were moderate, implying 
convergent validity. In addition when the HRQoL mark was compared with different 
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dimensions of QoL, the correlations were found to be moderately to high (negatively) 
correlated, also implying convergent validity. This finding is in line with earlier findings 
of De Boer and co-workers (2004 ). They used a VAS to record the overall HRQoL and 
found that the VAS was a valid and reliable method for measuring the global HRQoL. 
(De Boer et al., 2004 ). 
It should be emphasized that the individual approach has been introduced to explore 
possible agreements with standardized approaches. This has not (yet) been studied for its 
validity and reliability. However, the QoL mark shows a correlation with all the SF-36 
items, indicating a convergent valid measure. 
In conclusion, our explorative study showed that when patients were asked about their 
HRQoL in a structured, but open manner, they can and may report new, unknown facts 
or information, which has not been clarified in the history taking or in standardized as­
sessment. In addition, a short, individual approach of HRQoL provides insight in the pa­
tients' perception of the environment and provides extra information complementary to 
standardized methods, which may provoke further, thorough psychological assessment. 
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Genera l  d iscussion 

General d iscussion 
Pain is, by definition, an individual experience and is associated with tissue damage. 
However, somatic lesions usually are far less obvious in chronic pain than in acute pain 
conditions, and in many chronic pain cases a somatic lesion may not even exist any more 
at the time of examination. On the other hand, psychosocial factors play a major role in 
chronic pain conditions. As a consequence, diagnostic assessment in chronic pain is dif­
ficult and complex. 
Traditionally, diagnostic pain assessment is performed based on the assumption that tis­
sue damage (somatic origin) causes the pain and therefore, the focus should be on the 
search for this tissue damage (Feinmann, 2004). In essentialism, diseases are considered 
to be causal for illness. Therefore, the clinician is focused on identifying the disease and 
providing treatment. Still, from this point of view, clinicians and patients search for a 
biomedical explanation for the pain. When this explanation cannot be found, patients 
will undergo additional tests and even treatments, ever aiming at the identification of a 
somatic cause. When this fails, patients are frequently thought to be malingering or the 
pain is considered psychic in origin. 
More recently, the influence of psychosocial factors on the persistence of both acute and 
chronic pain have been widely acknowledged and incorporated in the diagnostic assess­
ment. However, this does not imply that chronic pain conditions are psychological or 
psychiatric in nature, which should be approached accordingly. Nevertheless, both the 
medical model and the psychosocial model focus on causal explanations. In analogy to 
the essentialists' hunting for the causation of illness, such an approach harbours some 
flaws as the etiology of many diseases remain of unknown origin, known causes are of 
diverse types, and causation can be intricate and involve interaction with other factors 
(Scadding, 1996 ). In such cases, an approach is preferred which recognizes these flaws 
and eventually aims at treatment of the patient with the disease rather than treatment of 
the disease. "Nominalists definitions do not attempt the impossible task of revealing the 
essence of the definiendum, but state how words or other symbols are to be related to 
observable phenomena" (Scadding, 1988). 
We have proposed an approach in which the focus is on one or more Stimulus-Pro­
cessing-Consequences (SPC) levels, to enhance and enrich the diagnostic assessment in 
chronic orofacial pain. 
stimulus > processing 
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Current research in orof acial pain 
After assessing existing studies on diagnostic tests in orofacial pain, using a minimum set 
of criteria including the presentation of selection criteria, randomization and blinding, it 
became clear that: • only cases of well defined orofacial pain types have been studied properly. • only a minority of all diagnostic research seems to be of sufficient quality. 
This implies two main issues in current pain research. First, patients with orofacial pain 
with clinical presentation, suiting a diagnosis in a current classification system may rela­
tively easily be included in clinical research, as inclusion criteria (i.e. diagnostic criteria) 
are relatively obvious. In orofacial pains in which causes are more obscure, this will be 
more difficult. So the challenge in diagnostic test development remains for the less obvi­
ous, mainly chronic idiopathic orofacial pains. Secondly, if diagnostic tests as such are 
studied, the trial should be well designed, thereby enhancing the quality and value of 
the assessment, diagnosis and treatment of chronic orofacial pain. The purpose of con­
ducting diagnostic research in this context is the development of valid diagnostic tests. 
Therefore, a minimum of criteria should be obeyed to draw firm conclusions based on 
the research's results. The results from our review ( chapter 2) signify the importance of 
using standard quality measures in conducting studies, and the consequences of proper 
reporting of the applied quality measures in research papers. It could well be that in some 
studies most criteria were fulfilled, but not reported. Although seemingly disappointing, 
it should function as an encouragement for future research(ers) in order to enhance the 
quality and relevance of their diagnostic research in chronic orofacial pain. 
Pharmacodiagnostics 
When focusing on the stimulus and processing levels, pharmacodiagnostic methods 
are potentially valuable. Locally acting pharmcodiagnostics could be of help in locat­
ing the structure from which the pain emanates from i.e. the source of pain. Together 
with careful history taking, the source of pain may be established by using clinical tests 
aimed at provocation of pain or using diagnostic anesthesia aimed at eliminating the 
pain response. In acute pain, e.g. when pulpitis is suspected ( characterized by its poor 
localizability), this is done to locate the painful tooth. In the assessment and treatment 
of chronic orofacial pain conditions, diagnostic anesthesia can also be helpful. In one 
type of orofacial pains, temporomandibular disorders (TMD), anesthesia may be used to 
specify the origin of the pain, i.e. to find out whether the pain is of articular origin or not. 
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This is especially important when it has far-reaching consequences ( e.g. as indication for 
invasive c.q. surgical treatment). We showed that injection of anesthesia in the tempo­
romandibular joint (TMJ) causes more pain relief than placebo injection. However, the 
anesthesia did not completely diminish the pain in all cases, which may be due to the in­
volvement of nearby structures, for instance in the case of temporomandibular disorders 
with both articular and muscular involvement or compensation. The (in)complete pain 
diminishing effect may also be due to anatomical, physiological or psychological factors 
in individuals, such as the duration of pain experience, the reproducibility of the anesthe­
sia technique, the (in)ability to use of a standardized dosage in each patient, the coping 
strategies of the individual and the anticipation on the effects of the administered drug. 
These factors must be constantly kept in mind when using this diagnostic test. Therefore, 
to rule out the possibility of a false positive response, repeated anesthetic injections and 
the use of placebo injections may give indications of the reliability of the response. This 
is especially advisable when the injection suggests an intra-articular origin of pain im­
plying the need for further irrevocable treatment. Alternatively, to confirm an articular 
origin, anesthesia of the nervus auriculotemporalis could be considered, although it is not 
completely responsible for innervation of the TMJ (Donlon et al, 1984 ). 
In addition to local pharmacodiagnostics, systemic pharmacodiagnostics make use of 
the response of patients to different pharmacological agents. In a first attempt to study 
whether a pharmacodiagnostic test could be an aid in disentangling chronic pain patients, 
early findings revealed that this test was well tolerated, and that in nearly one third of 
the patients tested, a classification of the underlying pain mechanism could be based on 
the response to the test. Although classification of only one third of patients may seem 
disappointing, one. must take the patient population into consideration: all patients had 
chronic pain that could not be diagnosed based on history, clinical and additional ( e.g. 
imaging) information. 
Against this background, the ability to classify a third of these patients is useful and a 
step in the right direction. Moreover, the ability to classify patients based on a phar­
macodiagnostic test was in turn dependent on the effects of fixed low-dose amounts of 
pharmacological agents in a heterogeneous patient sample. Therefore, the value of the 
classification of the test needed to be validated. 
N ociceptive, neuropathic, and sympathetically maintained pain (SMP) are currently 
considered to be the three main pain mechanisms. Therefore, three distinct groups of pa­
tients (with nociceptive, neuropathic, and SMP) were selected and underwent a slightly 
simplified version of the test, i.e. without thiopental. In the validation study, the pharma­
cological test seemed to be able to differentiate between the three different pain catego­
ries. However, it was not possible to determine one or more test components that could 
truly identify a single mechanism (or a combined pattern of mechanisms). A multi-level 
analysis was used, as it respects the dependency of the different drug deliveries (and 
different Visual Analogue Scale scores) within one patient at one level, and the patient 
groups c.q. the pain groups at a second level. Our study was performed in patients whose 
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diagnoses were based on clinical characteristics; it is possible that in some of these pa­
tients multiple pain mechanisms were present. This could be an explanation why not all 
patients within each group responded similarly. Nevertheless, throughout the course of 
the test, the test could differentiate between the three pain groups. It would be desirable 
to be able to use this test in patients with pain of unknown mechanisms. In these patients, 
the pain may be the result of a combination of the different mechanisms, with one of 
these mechanisms playing the major role. When the test is applied to those patients, the 
(major) pain mechanisms may be elucidated. In order to draw firm conclusions, future 
research should focus on enhancing the test, and the clinical implications of test out­
comes, i.e. basing and evaluating treatment on test outcomes. 
The performance of the test may be (further) enhanced by using specific pharmacological 
agents and adapting the applied dosages to the individual's response. As clearly studied 
and reported, pain chronicity involves a variety of neuroplastic changes which may also 
affect the responses to these agents. Somatosensory phenomena such as hyperalgesia, 
hypesthesia and dysesthesia were not taken into account in test responses. But even when 
neuroplastic changes have occurred, testing patients may be of help in determining an ab­
sence of peripheral mechanisms and thus excluding possible peripheral treatment. When 
a pharmacological test is used in an early stage, peripheral mechanisms may still be active. 
Quality of Life 
When focusing on the consequences of pain, the results of our quality of life (QoL) 
studies show that when temporomandibular pain lasts longer, quality of life becomes 
more affected. This has been assumed in temporomandibular disorders, but evidence was 
scarce. When dividing patient population in three groups according to duration of pain, 
and also when taking the pain duration as a continuous variable, it becomes obvious that 
there is a difference between groups of different pain duration concerning physical and 
social functioning. Although outcomes may meet the expectations, this study confirms 
what has been previously assumed. Accordingly, treatment strategies can be based on 
these findings, paying more attention to social factors in patients with pain lasting for a 
longer period of time. 
Although not yet studied for validity and reliability, asking patients to rate one domain 
that is of influence on their quality of life and asking them to rate their QoL using a mark 
provides a quick indication and may serve as point of departure for further investigations. 
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When a low QoL is scored, further elucidation by more detailed questions and questions 
addressing the major determinant of the low score are indicated. A recent study showed 
that the impact of the TMD on the QoL was related to the type of TMD (Barros V de 
et al, 2009). As shown in our previous study: the longer pain problems last, the more 
pronounced the effects on the QoL. So especially in these patients, using a brief indicator 
is recommended, giving attention to and recognition of the psychosocial consequences 
which, together with assessment of other levels of the pain, has a synergistic effect. 
Future perspectives 
Current and future research on orofacial pain takes place at different levels. Focusing 
solely on one level may lead to inadequate pain management, as different levels of pain 
are involved. 
In the development of pharmacodiagnostics, an individually tailored set-up should be 
developed and investigated to improve the distinguishing capacity. The value of using 
pharmacodiagnostics in predicting treatment outcome should also be studied. Although 
this strategy focuses mainly on the somatic aspect it could, in combination with psycho­
logical assessment, contribute to proper assessment and treatment of chronic orofacial 
pain patients. 
Evidence for the use of new or current assessment and treatment modalities for chronic 
pain patients should be established more firmly. In randomized, placebo controlled trials 
evaluation of currently used (and seemingly successful, but yet not proven) treatment 
should be done. Difficulties in generalizability of patient cohorts with unclear diagnosis 
may be overcome by the development of a new classification system which differentiates 
alternative and redefined current rationales. 
Further development and extension of knowledge should take place at a basic science 
level, i.e. molecular processes, genetic variability and "susceptibility" of chronic pain 
patients. In search of etiological factors and treatment modalities for chronic pain, the 
transition of acute pain into chronic pain deserves broad attention. When the factors are 
identified that enable the pain to persist, chronic pain may be prevented. 
It is not your duty to complete the work, but neither are you free to desist from it. (Avot 2:15) 
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Orofacial pain is a common reason for a patient to visit the physician or dentist. In most 
cases, diagnosis will be relatively straightforward and an adequate treatment can usually 
be provided. When pain persists over time (i.e., when pain becomes chronic), this will 
hamper the diagnostic process by so called neuroplastic changes of the nervous system. 
Because of these physiological and biochemical changes, a normally non-painful stimulus 
may be perceived as painful. Neuroplastic changes may also explain the phenomenon of 
referred pain, i.e. pain is perceived in an area that is different from the source from where it originates. Moreover, chronicity leads to an increased involvement of psychosocial 
factors in the perception and experience of pain, which further complicates the problem. 
To diagnose pain, different classification systems have been developed. In these classifi­
cations, the pain conditions are usually described in terms of symptomatology. When the 
clinical presentation of symptoms becomes less clear, e.g. because of changes related to 
chronicity, classification will be more difficult. This will eventually have consequences 
for pain management. Especially for this patient group, there is a need for additional 
diagnostic information which may clarify the clinical picture. The aim of this thesis is to 
enhance the diagnostic assessment of chronic orofacial pain. 
Irrespective of the complexity of the pain, it will essentially originate from actual or 
former tissue damage. This stimulus is subsequently processed within the nervous sys­
tem and will eventually give rise to certain responses, i.e. pain experience and behavior 
(consequences). Thus, in the pain process essentially three components are involved: 
stimulus, processing and consequences. We therefore introduce the stimulus-processing­
consequences (SPC) model as a starting point for the assessment of pain. 
In most patients pain with acute pain, tissue damage plays a major role, while the pro­
cessing of the stimuli is unaffected. Therefore, diagnosis and treatment of these patients 
will mainly focus on the stimulus. In patients with chronic pain, tissue damage will play 
a less dominant role and the consequences will largely be accompanied by changes in the 
processing of the stimuli. In this group, it is therefore important to not solely focus on 
the stimulus (the origin and extent of tissue damage), but to include explicitly the pro­
cessing of the stimulus and its consequences in the diagnostic assessment. 
In order to study the ( quality of) current diagnostic methods and their applicability in 
patients with persistent orofacial pain, the results of a systematic review are presented 
in chapter 2. The systematic review was conducted with specific search terms for clini­
cal studies in orofacial pain. Because it concerned diagnostic research, a methodological 
filter aiming at diagnostic research was applied. 
The search retrieved 1047 articles. Of these articles, the titles and abstracts were screened 
for relevance. In order to obtain qualitatively adequate studies, eventually 72 studies were 
assessed using the Quality Assessment of Diagnostic Accuracy Studies list (QUAD AS). 
This checklist consists of 14 items that refer to internal validity. We argued that studies 
scoring "yes" in more than half of the questions could be included for further appraisal. 
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This resulted in 15 qualitatively adequate studies. Of these studies, eight investigated the 
diagnostic value of magnetic resonance angiography for vascular compression in trigemi­
nal neuralgia. Three studies reported the diagnostic value of magnetic resonance imag­
ing in the temporomandibular joint (TMJ) arthralgia. The others studied a bite test for 
identifying muscular or articular origin of pain in the TMJ region, neurophysiological 
tests for the assessment of facial nerve deficits, the diagnostic validity of pain complaints 
and symptoms and pulpal tests in patients with pulpal problems, diagnostic anesthesia in 
intra-articular temporomandibular joint pain. This review demonstrates that when stud­
ies on diagnostic tests in orofacial pain conditions are reviewed, only a minority remains. 
Moreover, these studies predominantly aim at well-defined orofacial pain types, which 
are relatively well described and easy to diagnose. There is a large need for diagnostic 
methods aiming at (more) complex pain conditions, such as chronic orofacial pain. 
Chapter 3 aims at farmacodiagnostics: diagnostics using pharmacological agents. This 
focuses mainly on the stimulus (chapter 3.1) and the processing of the information within 
the nervous system (chapter 3.2 and 3.3). 
In chapter 3.1 a study is described in patients experiencing pain in the TMJ area. In these 
patients it is important to establish whether the pain originates from the joint proper. 
In the diagnostic process, intra-articular anesthesia has frequently been used. In this re­
search, the distinguishing capacity of intra-articular injection of anesthesia compared to a 
placebo is studied. In a double-blind placebo controlled cross-over trial, 19 patients who 
were clinically diagnosed with TMJ pain (arthralgia) were studied. Patients received both 
placebo and anesthesia injections, with a two weeks wash-out period between the injec­
tions. A computer program determined the order of the injections (randomization). Both 
placebo and anesthesia were delivered in identical carpules by the hospital pharmacy, 
in order to be sure that both the patients and the clinician were unaware of the injected 
substance (double-blinded). At the end of the study, the randomization code was broken. 
The anesthesia had a pain diminishing effect, measured on a Visual Analogue Scale (VAS, 
of 100 mm) of 12.8 mm (SD 23.5) compared to a pain increasing effect of the placebo 
of 4.5 mm (SD 15.0). This difference was statistically significant. It seems that intra­
articular anesthesia can be used as a diagnostic tool in these patients. However, it should 
be noted that there is always a chance that patients respond false positively to an injection 
and the injection should therefore be repeated, in order to verify the results. The results 
of an intra-articular injection should be interpreted with caution, especially when the 
results have far-reaching consequences, e.g. surgery. 
In chapter 3.2 the results of a retrospective study in 46 patients with chronic orofacial 
pain, undergoing a pharmacodiagnostic test (PDT), are described. In none of these pa­
tients, the history taking and standard clinical and radiographic examination revealed 
a proper diagnosis and treatment strategy. During the PDT, different pharmacological 
agents are subsequently delivered intravenously in a specific order. These agents are di­
rected to specific pain mechanisms. The test consisted of fentanyl and its antagonist na­
loxone (aiming at nociceptive pain), thiopental (aiming at central pain), phentolamine 
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(aiming at sympathetically maintained pain) and lidocain (aiming at neuropathic pain). 
These infusions were interchanged with placebo. Before the test and after each delivery 
the patients were asked to rate their pain on a VAS. When the VAS score decreased at 
least 33% compared to the baseline, the patients was classified as "responder". 
Out of 46 patients, eventually 16 could be classified as a responder to one or more of the 
pharmacological agents. The results of this study suggest that the pharmacodiagnostic 
test may offer valuable diagnostic information, especially in a patient group like this, 
where there is a need for additional information. 
To obtain more information regarding the value of this test, validation is required. The 
results of the study on this topic are described in chapter 3.3. In this trial, three groups 
underwent the pharmacodiagnostic test. • A group with nociceptive pain (a day after the extraction of their third molar) • Patients with neuropathic pain (from the Department of Neurology or Pain Center 
diagnosed with a mono- or poly neuropathy) • A group with sympathetically maintained pain (patients with the chronic regional 
pain syndrome and patients with a pain diminishing effect of a sympathicolytic pro­
cedure) 
Multilevel analysis, performed to correct for the effect of the subsequent infused agents 
in different patients in three pain groups, revealed that the pharmacodiagnostic test was 
capable of differentiating between the three pain groups. However, univocal classifica­
tion of an individual patient, based on the response on one or more parts of the tests, 
was not yet possible. The test should be further developed and modified, for instance by 
using individual dosages based on body weight or by titrating on effect. 
Focusing on the consequences of the pain, chapter 4 aims at 'quality of life' (QoL). It is 
generally assumed that QoL (a concept incorporating different aspects of physical and 
psychological health and social functioning) is an individual concept, which is affected 
by the duration of pain. In patients with temporomandibular disorders (TMD) this is 
also assumed, although not extensively studied. 
In the study described in chapter 4. 1 the influence of the duration of pain on the QoL 
was determined in 95 patients with a TMD. Different questionnaires assessing different 
aspects of quality of life were used in these patients. Patients were divided into three 
groups based on the duration of pain: one group with pain present less than 1 year, one 
group with pain present between 1 and 3 years and one group with pain more than 3 
years. Patients with pain which was present less than 1 year scored 'worse' than scores 
retrieved from a reference population. A significant correlation was found between 
physical functioning and mandibular impairment on one hand and pain duration on the 
other hand. It seemed that mental health was not, but social functioning was affected 
with a longer pain duration. These findings cannot be neglected and should therefore be 
incorporated in the assessment (diagnosis) as well as in the management of these patients. 
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Whether the assessment of quality of life can be limited to standardized questionnaires or 
an individualized approach has additional value is described in chapter 4.2. Besides using 
standardized QoL instruments and health questionnaires, 89 patients with a TMD were 
asked to indicate and rate a domain that most influenced their health related quality of 
life (HRQoL) and to rate their overall HRQoL with a mark ranging from O to 10. When 
patients were asked to depict a domain that influences their HRQoL, the domains health 
and family were indicated most frequently. This could not be retrieved using the cur­
rent standardized instruments. Furthermore, all correlations between the HRQoL mark 
and the standardized measures appeared to be statistically significant. This study shows 
that an individual approach of HRQoL may provide a relatively quick insight into the 
patients' perception of the environment and provides extra information concerning do­
mains determining (TMD) patients' quality of life. This may be a valuable starting point 
for further (psychological) diagnostic assessment. 
The discussion in chapter 5 reveals that pharmacodiagnosis serves a role in the process 
of enhancing the diagnostic armamentarium in chronic orofacial pain. The pharmacodi­
agnostic test seems to be able to differentiate between patients with pain different pain 
mechanisms that may also play a role in orofacial pain. Further enhancement of the test 
should take place, however, for instance by using individual dosages. The effect of treat­
ment could also be correlated to a specific test outcome. Besides this, the quality of life 
should be incorporated in the assessment of chronic pain patients. When pain persists, 
the quality of life will be negatively affected. The necessity of additional diagnostic as­
sessment and important domains of quality of life can be determined using simple ques­
tions. 
By involving different SPC levels simultaneously in pain diagnosis and by developing 
specific instruments for each of these levels, a synergistic effect on the efficacy of diag­
nostics and eventual management of chronic orofacial pain may be accomplished. 
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Samenvatting 
Pijn in de mond en het gebied van het aangezicht ( orofaciale pijn) is een belangrijke reden 
voor een patient om naar een tandarts of arts te gaan. In de meeste gevallen zal de diag­
nostiek relatief eenvoudig zijn en zal er snel een adequate behandeling ingezet kunnen 
worden. Indien de pijn langer aanwezig is (chronisch wordt), wordt de diagnostiek vaak 
bemoeilijkt door zogenaamde de effecten van neuroplastische veranderingen van het 
zenuwstelsel. Door deze veranderingen in fysiologie en biochemie kunnen gewoonlijk 
niet-pijnlijke prikkels nu wel als pijnlijk worden ervaren. Neuroplastische veranderin­
gen kunnen er ook toe leiden dat pijn op een andere plaats wordt gevoeld dan waar deze 
zijn oorsprong heeft (gerefereerde pijn). Chroniciteit leidt er ook toe dat psychosociale 
factoren een grotere rol gaan spelen bij de ervaring en beleving van de pijn, hetgeen het 
beeld vaak mede compliceert. 
Om pijn te diagnosticeren zijn diverse classificatiesystemen ontworpen. De beelden 
hierin zijn in de regel gedefinieerd op basis van de symptomatologie. Naarmate de kli­
nische presentatie van symptomen minder eenduidig wordt door de veranderingen die 
optreden als gevolg van chroniciteit, zal classificatie lastiger zijn. Dit zal uiteindelijk ook 
consequenties hebben voor de behandeling. Bij deze patienten is er een grote behoefte 
aan aanvullende informatie, die de klinische situatie kan verhelderen. Het doel van dit 
proefschrift is de mogelijkheden voor de beoordeling van chronische orofaciale pijn te vergroten. 
Hoe gecompliceerd pijn ook is, in essentie vindt deze zijn oorspong in actuele of vroe­
gere weefselschade. Deze vormt een stimulus, die vervolgens in het zenuwstelsel wordt 
verwerkt, hetgeen uiteindelijk aanleiding geeft tot bepaalde reacties, ervaringen en ge­
dragingen (consequenties). Bij het pijnproces zijn dus drie componenten betrokken: sti­
mulus, verwerking en consequentie. Wij introduceren daarom het stimulus-processing­
consequences (SPC) model als basis voor het beoordelen van pijn. 
Bij de meeste pijnpatienten speelt de weefselschade een hoofdrol en verloopt de ver­
werking van de prikkels ongestoord; diagnostiek en behandeling zullen zich bij deze 
patienten dan ook vooral op de stimulus richten. Bij patienten met chronische pijn speelt 
de weefselschade doorgaans een minder dominante rol en lijken de consequenties gro­
tendeels samen te hangen met veranderingen in de verwerking van de prikkels. Bij deze 
groep is het daarom van belang de diagnostiek niet uitsluitend te richten op de stimulus 
(de aard en omvang van weefselschade), maar hierbij de verwerking van prikkels en de 
consequenties nadrukkelijk te betrekken. 
Om een overzicht te krijgen van de huidige stand van zaken van (de kwaliteit van) het 
diagnostisch onderzoek bij orofaciale pijnen word en in hoof dstuk 2 de resultaten van een 
systematisch literatuuronderzoek weergegeven. Het literatuuroverzicht werd verricht 
met specifieke zoektermen voor klinische studies naar orofaciale pijn. Aangezien er werd 
gezocht naar diagnostisch onderzoek is hier een methodologisch filter voor gebruikt. 
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De zoekacties leverden 1047 artikelen op. Van deze artikelen werden de titels en samen­
vattingen onderzocht op relevantie. Om onderzoek te verkrijgen dat kwalitatief voldoen­
de was, zijn 72 relevante artikelen beoordeeld met behulp van de Quality Assessment of 
Diagnostic Accuracy Studies (QUADAS) lijst. Deze lijst bevat 14 onderdelen over in­
terne validiteit. Wij achtten studies van voldoende kwaliteit als de artikelen aan minstens 
de helft van de 14 onderdelen voldeden. Dit resulteerde in 15 diagnostische studies van 
voldoende kwalitatief. Acht hiervan gingen over de beoordeling van trigeminusneuralgie 
met behulp van magnetische resonantie angiografie. Drie studies onderzochten de waar­
de van beeldvorming met magnestische resonatie bij artralgie van het kaakgewricht. De 
overige studies onderzochten een bijttest voor de oorsprong van kaakgewrichtspijn, een 
zenuwgevoeligheidstest bij aandoeningen van zenuwen in het aangezicht, de relatieve di­
agnostische waarde van pijnklachten, symptomen en pulpatests bij patienten met pulpa­
problemen en het gebruik van lokale anesthesie bij de diagnostiek van kaakgewrichtspijn. 
Dit literatuuronderzoek illustreert dat er slechts een beperkte hoeveelheid kwalitatief 
adequaat onderzoek op het gebied van de diagnostiek van orofaciale pijn voorhanden is. 
Opvallend is dat deze studies veelal zijn gericht op vormen van orofaciale pijn die relatief 
goed omschreven en eenvoudig te diagnosticeren zijn. Aan onderzoek naar diagnostische 
methoden gericht op complexe(re) vormen van orofaciale pijn (bijvoorbeeld chronische 
orofaciale pijn) is dringend behoefte. 
Hoofdstuk 3 is gericht op de farmacodiagnostiek: diagnostiek met behulp van medica­
menten. Deze richt zich met name op de stimulus (hoofdstuk 3.1) en be:invloeding van de 
verwerking (processing) van prikkels (hoofdstukken 3.2 en 3.3). 
In hoofdstuk 3.1 wordt een onderzoek beschreven bij patienten die pijn ervaren in het 
gebied van het kaakgewricht. Bij deze patienten is het van belang vast te stellen of de pijn 
zijn oorsprong heeft in het gewricht zelf. Hiertoe wordt in de diagnostiek wel gebruik 
gemaakt van intra-articulaire lokale anesthesie. In dit onderzoek wordt het onderschei­
dend vermogen van intra-articulaire injectie van een lokaal anesthesticum ten opzichte 
van een placebo onderzocht. In een dubbelblinde cross-over opzet werden 19 patienten, 
klinisch gediagnosticeerd met kaakgewrichtspijn (arthralgie), onderzocht. Patienten kre­
gen een injectie met zowel een lokaal anestheticum als een placebo, met een periode van 
twee weken tussen deze twee injecties. Door een computerprogramma werd de volgorde 
van injectie bepaald (randomisatie). Beide vloeistoffen werden door de ziekenhuisapo­
theek in identieke carpules geleverd, waardoor zowel de patient als de arts op het mo­
ment van injectie niet wisten welk middel werd toegediend ( dubbelblind onderzoek). 
Aan het einde van de studie werd de randomisatie onthuld. 
De lokale anesthesie had een pijnverminderend effect, zoals werd vastgesteld op een Vi­
suele Analoge Schaal (VAS) van 100 mm, van 12.8 (SD 23.5) ten opzichte van een pijn­
verhogend effect van de placebo van 4.5 (SD 15.0). Dit verschil was statistisch significant. 
Het gebruik van intra-articulaire anesthesie lijkt dus gebruikt te kunnen worden als diag­
nostisch instrument bij deze patienten. Wei moet warden opgemerkt dat de kans bestaat 
dat patienten ten onrechte positief reageren op een toegediende injectie en dat wellicht 
herhaling van de injectie nodig is om de uitkomst te verifieren. De resultaten van een 
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intra-articulaire injectie zullen dus voorzichtig moeten worden gei:nterpreteerd, vooral 
als de uitslag verregaande consequenties (bijvoorbeeld een chirurgische ingreep) heeft. 
In hoof dstuk 3 .2 word en de resultaten weergeven van een retrospectief onderzoek bij 
46 patienten met chronische orofaciale pijn, die een farmacodiagnostische test (FDT) 
ondergingen. Bij geen van deze patienten leidde de anamnese en het standaard klinisch 
onderzoek aangevuld met rontgenologische informatie tot een duidelijke diagnose en be­
handeling. Tijdens de FDT worden verschillende farmaca na elkaar en in een vaste volg­
orde intraveneus toegediend. De farmaca zijn gericht op verschillende pijnmechanismen. 
De test bestaat uit fentanyl met zijn antagonist naloxon (gericht op nociceptieve pijn), 
thiopental (gericht op centrale pijn), fentolamine (gericht op sympathisch gemedieerde 
pijn) en lidocaine (gericht op neuropathische pijn). Deze onderdelen worden afgewisseld 
met de toediening van fysiologisch zout. Voorafgaande aan de test en volgend op elke 
toediening wordt aan de patient gevraagd de pijn op een VAS weer te geven. Wanneer de 
VAS score na toediening van een stof met minstens 33 % ten opzichte van de baseline ver­
anderde, werd de patient met betrekking tot dit farmacon geclassificeerd als "responder". 
Van de 46 patienten konden uiteindelijke 16 patienten worden geclassificeerd als "res­
ponder" op een of meer farmaca. De resultaten van deze studie suggereren dat de far­
macodiagnotische test waardevolle informatie kan opleveren, gegeven de aard van de 
patientengroep, waarbij immers aanvullende diagnostische informatie welkom is. 
Om over de waarde van de test extra informatie te verkrijgen, is het echter nodig om de 
test te valideren. De resultaten van het onderzoek hiernaar staan beschreven in hoofdstuk 
3.3. In dit onderzoek ondergingen drie groepen pijnpatienten de farmacodiagnostische 
test: • een groep met nociceptieve pijn (een dag na verwijdering van een verstandskies) • een groep met neuropathische pijn (vanuit de afdeling neurologie of het pijncentrum 
gediagnosticeerde patienten met een mono- of polyneuropathie) • een groep met sympatisch gemedieerde pijn (chronisch regionaal pijnsyndroom I en 
met pijnvermindering na een sympathicolytische procedure) 
Na een multi-level analyse, uitgevoerd om de effecten van de na elkaar toegediende mid­
delen in de verschillende patienten in de drie groepen te bestuderen, bleek dat de far­
macodiagnostiche test in staat is om de drie pijngroepen van elkaar te onderscheiden. 
Eenduidige classificatie van een individuele patient op basis van de respons op een of 
meerdere onderdelen van de test bleek echter nog niet mogelijk. Hiervoor zal verdere 
ontwikkeling en modificatie van de test plaats moeten vinden, waarbij te denken valt aan 
een individuele dosering gebaseerd op lichaamsgewicht of aan titratie op effect. 
Met een focus op vooral de gevolgen (consequences) van pijn richt hoofdstuk 4 zich op 
de kwaliteit van leven. Over het algemeen wordt aangenomen dat de kwaliteit van leven 
( een concept dat verschillende componenten bevat, zoals fysieke en psychische gezond­
heid en sociale aspecten) een individueel concept is, dat onder meer wordt bei:nvloed 
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door de duur van het bestaan van pijn. Ook bij patienten met aandoeningen van het 
mandibulaire bewegingsapparaat wordt dit verondersteld, hoewel dit is niet uitvoerig 
onderzocht. 
In het onderzoek dat beschreven is in hoofdstuk 4.1 werd de invloed van de duur van 
aanwezigheid van de pijn op de kwaliteit van leven bepaald bij 95 patienten met een aan­
doeningen van het mandibulaire bewegingsapparaat. Bij deze patienten werden verschil­
lende vragenlijsten afgenomen die betrekking hebben op verschillende aspecten van de 
kwaliteit van leven. De patienten werden verdeeld in drie groepen op basis van de duur 
van de aanwezigheid van de pijn: een groep met pijn die minder clan 1 jaar aanwezig was, 
een groep met pijn die tussen 1 en 3 jaar aanwezig was en een groep met pijn die langer 
dan 3 jaar bestond. Patienten met pijn langer dan een jaar scoorden slechter dan een refe­
rentie populatie op zowel fysiek als sociaal functioneren. Ten aanzien van mentale items 
verschilden geen van de groepen met de referentie populatie. Er werd een significante 
correlatie gevonden tussen fysiek functioneren en mandibulaire beperking aan de ene 
kant en duur van de pijn aan de andere kant. Het lijkt er dus op dat de mentale gezond­
heid vrijwel niet wordt aangetast door een langere duur van pijn, maar dat het sociale 
functioneren wordt bei:nvloed door langdurige aanwezigheid van pijn. Deze bevinding 
kan niet worden genegeerd en hieraan zal zowel bij de beoordeling ( diagnostiek) alsook 
bij de behandeling van deze patienten clan ook aandacht moeten worden besteed. 
Of de beoordeling van de kwaliteit van leven het beste met gestandaardiseerde vragen­
lijsten kan worden uitgevoerd of dat een individuele benadering daarbij een meerwaarde 
heeft, wordt beschreven in hoofdstuk 4.2. Naast gestandaardiseerde kwaliteit van leven 
vragenlijsten en gezondheidsvragenlijsten werd er aan 89 patienten met een aandoening 
van het mandibulaire bewegingsapparaat gevraagd om aan te geven wat het belangrijkste 
aspect is van hun kwaliteit van leven en hoe zij dit aspect persoonlijk waarderen. Ook 
werd aan deze patienten gevraagd hun "overall" kwaliteit van leven te waarderen met 
een rapportcijfer (0-10). Deze patienten gaven duidelijk aan dat "gezondheid" en "fa­
milie" belangrijke aspecten zijn die hun kwaliteit van leven bepalen. Dit kwam echter 
uit de gestandaardiseerde vragenlijsten niet naar voren. Verder bleek het gegeven rap­
portcijfer met alle onderzochte gestandaardiseerde items significant te correleren. Uit dit 
onderzoek blijkt dat een individuele benadering snel inzicht kan geven in de aspecten die 
door patienten met een aandoening van het mandibulaire bewegingsapparaat als bepa­
lend voor hun kwaliteit van leven worden ervaren. Dit geeft samen met een eenvoudige 
"overall" waardering van de kwaliteit van leven inzicht in de noodzaak van en een goede 
uitgangssituatie voor verder diagnostisch (psychologisch) onderzoek. 
Uit de discussie in hoofdstuk 5 komt naar voren dat bij het vergroten van het diagnos­
tische arsenaal bij orofaciale pijn een rol is weggelegd voor de farmacodiagnostiek. De 
farmacodiagnostische test lijkt onderscheid te kunnen maken tussen patienten met ver­
schillende pijnmechanismen die ook een rol spelen bij orofaciale pijn. Verdere verfijning 
van dit instrument client echter plaats te vinden, onder meer door met gei:ndividualiseer­
de doseringen te werken. Ook zou het effect van een uitgevoerde behandeling kunnen 
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worden gecorreleerd aan een bepaalde testuitslag. Hiernaast zal de kwaliteit van leven 
moeten worden meegenomen bij de evaluatie van chronische pijnpatienten. N aarmate 
pijn langer bestaat, zal de kwaliteit van leven nadelig worden be'invloed. De noodzaak 
van verder onderzoek en de belangrijkste bijdragende aspecten van de kwaliteit van leven 
kunnen aan de hand van simpele vragen worden vastgesteld. 
Door de verschillende SPC niveaus gezamenlijk bij de pijndiagnostiek te betrekken en op 
elk van deze niveau's gerichte instrumenten te ontwikkelen kan een synergistisch effect 
op de doelmatigheid van de diagnostiek en uiteindelijk de behandeling van chronische 
orofaciale pijnpatienten worden bereikt. 
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tegengas als alternatief voor jouw achternaam geeft. Door jouw voortvarendheid en kri­
tische houding heeft deze moeilijke materie zich laten vangen in dit mooie boekje. Mijn 
waardering voor jou gaat verder clan alleen als onderzoeksbegeleider en ik beschouw je 
clan ook als een wijze man. Dank voor je inzet en vertrouwen, ik hoop dat we hierna sa­
men nog meer mooie projecten kunnen aangaan. Ik ben blij dat je mijn eerste promotor 
bent. 
Prof. dr. De Bont. Mede door u en ook uw voorganger prof. dr. Boering heeft de afdeling 
kaakchirurgie een grote traditie en reputatie in de orofaciale pijn en kaakgewrichtsstoor­
nissen. Dank dat u mij de mogelijkheid hebt gegeven hierin onderzoek te doen, op een 
afdeling met fijne collega's. Uw adviezen hebben de manuscripten en ook mij scherper 
gemaakt. 
Dr. Van Wijhe. Beste Marten, in het UMCG heb je blijk gegeven op een alternatieve 
manier naar chronische pijnpatienten te kunnen kijken. De ontwikkeling van de test is 
daar een voorbeeld van. Laat de resultaten van ons onderzoek een stimulans te zijn om 
met deze ontwikkeling door te gaan ten faveure van de pijnpatienten. Bedankt voor je 
adviezen en medewerking. 
Dr. Huddleston Slater. Beste James, door jouw komst op o.a. de afdeling(en) is de con­
tinuering van de aandacht voor zowel de gnathologie als de epidemiologie, maar ook 
kritische denkwijze gewaarborgd. Ik ben blij dat je besloot mee te willen werken aan een 
aantal stukken en heh van je kritische houding en originaliteit geleerd. Dank voor je inzet 
en inbreng in mijn onderzoek. 
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Drs. Reinders. Beste Jan-Jaap, als buurman op de universiteit kwam je buurten met op­
rechte interesse, die mij steeds duidelijk werd door je zinvolle kritische en doordachte 
gedachten over o.a. mijn manuscripten. Grappig dat je van buurman mede-auteur werd, 
je visie heeft zeker mijn kwaliteit van leven vergroot! 
Dr. Ten Vergert. Beste Els, je adviezen ook vanuit een niet vakinhoudelijk perspectief 
waren zeer verhelderend. Jammer genoeg heh je niet het hele promotietraject mee kun­
nen maken maar ik hen je dankbaar voor je bijdragen. 
De leden van de beoordelingscommissie; prof.dr. De Laat, prof.dr. Huygen en prof.dr. 
Kuks wil ik graag bedanken voor de beoordeling van het manuscript. 
Mijn collega's van de afdeling Kaakchirurgie op met name de derde verdieping en elders; 
bedankt voor de inspirerende, onzinnige, gei"nteresseerde, opbeurende, relativerende ge­
sprekken van de afgelopen tijd. Van de bezoeken aan de Society of Oral Physiology 
(Storekro) in Naantali en Dresden hebben ik in meerdere opzichten iets geleerd. 
Mw. Dam. Beste Anne-Margreeth, jij hebt je ontfermd over de uitvoering en planning 
FDT's wat niet altijd een eenvoudige klus was. Toch is het gelukt. Bedankt voor je inzet! 
Collega's van het pijncentrum bedankt voor jullie medewerking. 
Prof. Dr. Abbas. Beste Frank, in wat ik dacht wat de laatste fase was van de vervaardiging 
van mijn manuscript kwam ik bij je voor een informatief gesprek over de parodontolo­
gie. Dat dit gesprek zo zou lopen als dat het liep had ik niet kunnen hopen. Mede door 
de vrijheid die ik kreeg in de laatste maanden heh ik dit manuscript kunnen afronden. 
Bedankt voor het vertrouwen en de gelegenheid die jij me biedt om me te bekwamen in 
de parodontologie. 
Collega's van het Centrum voor Tandheelkunde en Mondzorgkunde, binnen als buiten 
de sectie Parodontologie, dank voor jullie belangstelling en enthousiasme. 
Heleen bedankt voor je begeleiding tijdens de opleiding totnutoe en je interesse in mijn 
onderzoek en de gezelligheid (o.a. tijdens de chirurgie !). 
Renske, collega, kamer/studie/lotgenoot; je was mijn docent toen ik begon aan de studie 
tandheelkunde en ik vind het leuk dat ik nu jou af en toe wat wijs kan maken. 
Prof. Dr. Loos. Beste Bruno, allereerst dank dat je mij hebt aangenomen. Het afronden 
van mijn proefschrift was daarbij een vereiste en ligt nu voor je. Dank voor je vertrou­
wen. 
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Prof. Dr. Van der Velden. Beste Ubele, in 2008 begon ik met de opleiding tot parodon­
toloog, waarbij ik sindsdien onder de indruk hen van je enthousiasme voor het vak en 
je drang naar kennis over elke uithoek van de parodontologie. Dit werkt inspirerend en 
heeft zelfs in dit boekje in ieder geval al z'n effect gehad. Wie weet wat volgt. 
Al mijn andere "leermeesters" en collega's op het ACTA, in het bijzonder (in willekeu­
rige volgorde) Wouter S, Tiddo, Ingrid, Fridus, Moniek, Spiros, Guido, Sergio, Dagmar, 
Fabiano, Yossi, Wouter v W, Elena, Wijnand. Bedankt voor jullie interesse voor het on­
derzoek gaandeweg de opleiding en natuurlijk jullie wijsheid! 
Fam. Prins, beste Luuk en Hennie. Luuk, jij hebt mij zowel als tandarts en daarmee au­
tomatisch als mens opgevoed. Als ik bij mijn eerste waarneming niet bij jullie terecht kon 
gekomen, was ik niet wie ik nu hen. En daar heh ik geen spijt van gehad. Ik had me geen 
betere eerste waarneming kunnen wensen. 
Beste Wouter, het was toeval dat jij mijn jaargenoot werd in de opleiding, maar ik vind 
het bijzonder dat dit redelijk snel tot vriendschap heeft geleid, waarbij je nuchtere karak­
ter een relativerende werking op mij heeft gehad. Dank voor jouw en Erin's gastvrijheid 
tijdens verschillende verblijven in Amsterdam. Ik vind het bijzonder dat je mijn paranimf 
wilt zijn. 
Beste Ger, lieve Ger. Al vanaf de basisschool was je de olijke (immer vriendelijke) krul­
lebol. In onze studietijd is de vriendschap ge'intensiveerd doordat je "bij ons" kwam 
wonen. Sindsdien hebben we veel contact, met een plezierige afwisseling tussen enorm 
kazen, kolder en jolijt en serieuze gesprekken. Ook heh ik de afgelopen jaren lange tijd 
van je onuitputtelijke gastvrijheid gebruik mogen maken. Ik hoop en ga er van uit dat we 
onze vriendschap in de toekomst voort zetten. Bedankt mijn paranimf wilt zijn. 
Lieve vrienden; door jullie vriendschap alsook interesse heb ik het vol kunnen houden en 
hoop ik meer tijd voor jullie vrij te kunnen maken. 
Niet los daarvan kan de band worden gezien met daarbij iedereen die daar ooit in heeft 
gespeeld of in had willen spelen, of die wij er graag in zouden zien spelen en de crew er­
omheen. Mijn onderzoek heeft onze internationale doorbraak enigszins vertraagd (nou, 
daar had ie dan weer geen tijd voor ... ), maar ik beloof deze achterstand binnenkort ruim­
schoots in te gaan halen! 
Lieve Annie en Roelf, vaak was ik bezig met mijn onderzoek, jullie hebben daar altijd be­
grip voor gehad en mij uit de wind gehouden. Dank voor jullie onvoorwaardelijke steun. 
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Lieve familie, lieve papa, mama en Mariken. Nog iemand in de familie die een boekje 
heeft geschreven. Bedankt voor jullie steun, niet alleen voor, maar ook tijdens het on­
derzoek. Mariken, jij hebt mij leren ontwikkelen buiten de verplichte lesuren om. Het 
kan niet anders of dat heeft de voorzet gegeven tot hetgeen nu voor je ligt. Papa, een van 
mijn inspiratiebronnen, mama, een van mijn trouwste fans en natuurlijk schilderes van 
de omslag. Ik dank jullie voor jullie steun en jullie interesse en (fysieke en emotionele) 
inbreng. Jullie zijn mijn steun en toeverlaat en waardeer dat meer dan jullie weten. Ik 
hou van jullie. 
Lieve Kina. Zonder mijn studie had ik jou niet gevonden, zonder jouw studie had ik mijn 
huidige opleiding niet gedaan. Zonder jou was ik niet waar en was ik niet wie ik nu ben. 
Kortom, jij hoort bij mij. En daar komt straks nog iemand anders bij. Zonder jou was ik 
al ik weet niet hoe vaak gestopt met mijn onderzoek, maar jij liet mij het belang maar ook 
de relativiteit ervan inzien. En dat is nog maar een klein deel van je invloed op mij. Hoe 
is het mogelijk dat andere mensen het volhouden zonder jou? Ik ben blij al bijna tien jaar 
met jou te mogen doorbrengen. Dit is nog maar het begin. Tijd om de bladzijde om te 
slaan, naar een nieuw hoofdstuk. .. ik hou van je. 
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